Multi-Drug Rapid Test Cup With Adulteration (Urine)

Package Insert

Instruction Sheet for testing of any combination of the following drugs: AMP/BAR/BZO/BUP/COC/THC/MTD/MET/MDMA/MOP/MQL/OPI/PCP/PPX/T CA/TML/KET/OXY/COT/EDDP/FYL/K2/6-MAM/MDA

Including Specimen Validity Tests (S.V.T.) for:

Oxidants/PCC, Specific Gravity, pH, Nitrite, Glutaraldehyde and Creatinine A rapid test for the simultaneous, qualitative detection of multiple drugs and drug metabolites in human urine. For healthcare professionals including professionals at point of care sites. Immunoassay for invitro diagnostic use only.

[INTENDED USE]

The Multi-Drug Rapid Test Cup is a rapid chromatographic immunoassay for the qualitative detection of multiple drugs and drug metabolites in urine at the following cut-off concentrations:

Test	Calibrator	Cut-off (ng/mL)
Amphetamine (AMP1,000)	d-Amphetamine	1,000
Amphetamine (AMP 500)	d-Amphetamine	500
Amphetamine (AMP 300)	d-Amphetamine	300
Barbiturates (BAR 300)	Secobarbital	300
Barbiturates (BAR 200)	Secobarbital	200
Benzodiazepines (BZO 500)	Oxazepam	500
Benzodiazepines (BZO 300)	Oxazepam	300
Benzodiazepines (BZO 200)	Oxazepam	200
Benzodiazepines (BZO 100)	Oxazepam	100
Buprenorphine (BUP)	Buprenorphine	10
Cocaine (COC 300)	Benzoylecgonine	300
Cocaine (COC 100)	Benzoylecgonine	100
Marijuana (THC150)	11-nor-Δ9-THC-9 COOH	150
Marijuana (THC 50)	11-nor-Δ9-THC-9 COOH	50
Marijuana (THC 25)	11-nor-Δ9-THC-9 COOH	25
Manjuana (TTC 23) Methadone (MTD 300)	Methadone	300
Methadone (MTD 200)	Methadone	200
Methamphetamine (MET 1,000)	d-Methamphetamine	1,000
Methamphetamine (MET 500)	d-Methamphetamine	500 300
Methamphetamine (MET 300) Methylenedioxymethamphetamine	d-Methamphetamine	
MDMA 500) Methylenedioxymethamphetamine	tamine	500
MDMA 1,000)	tamine	1,000
Morphine (MOP 300)	Morphine	300
Morphine (MOP 100)	Morphine	100
Methagualone(MQL)	Methaqualone	300
Dpiate (OPI 2,000)	Morphine	2,000
Phencyclidine (PCP)	Phencyclidine	2,000
Propoxyphene (PPX)	Propoxyphene	300
Tricyclic Antidepressants (TCA)	Nortriptyline	1,000
Framadol (TML)	Cis-Tramadol	1,000
Ketamine (KET 1,000)	Ketamine	1,000
Ketamine (KET 500)		500
· · · · ·	Ketamine	
Ketamine (KET 300)	Ketamine	300
Ketamine (KET 100)	Ketamine	100
Dxycodone (OXY)	Oxycodone	100
Cotinine(COT200)	Cotinine	200
Cotinine(COT100)	Cotinine	100
2-ethylidene-1,5-dimethyl- 3,3-diphenylpyrrolidine (EDDP300	2-ethylidene-1,5-dimethyl-)3,3-diphenylpyrrolidine	300
2-ethylidene-1,5-dimethyl- 3,3-diphenylpyrrolidine (EDDP100		100
Fentanyl(FYL20)	Norfentanyl	20
Fentanyl(FYL10)	Norfentanyl	10
Synthetic Marijuana (K2-50)	JWH-018、JWH-073	50
Synthetic Marijuana (K2-30)	JWH-018、JWH-073	30
6-MAM10)	6-MAM	10
±) 3,4-Methylenedioxy- Amphetamine(MDA500)	(±) 3,4-Methylenedioxy- Amphetamine	500
Ethyl- β-D-Glucuronide(ETG500)	Ethyl- β -D-Glucuronide	500
Ethyl- β-D-Glucuronide(ETG1.000	Ethyl- β -D-Glucuronide	1,000

Configurations of the Multi-Drug Rapid Test Cup come with any combination of the above listed drug analytes with or without S.V.T. This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

SUMMARY

The Multi-Drug Rapid Test Cup is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes monoclonal antibodies to selectively detect elevated levels of specific drugs in urine.

Amphetamine (AMP 1,000)

Amphetamine is a Schedule II controlled substance available by prescription (Dexedrine®) and is also available on the illicit market. Amphetamines are a class of potent sympathomimetic agents with therapeutic applications. They are chemically related to the human body's natural catecholamines: epinephrine and norepinephrine. Acute higher doses lead to enhanced stimulation of the central nervous system (CNS) and induce euphoria, alertness, reduced appetite, and a sense of increased energy and power. Cardiovascular responses to amphetamines include increased blood pressure and cardiac arrhythmias. More acute responses produce anxiety, paranoia, hallucinations, and psychotic behavior. The effects of Amphetamines generally last 2-4 hours following use and the drug has a half-life of 4-24 hours in the body. About 30% of amphetamines are excreted in the urine in unchanged form, with the remainder as hydroxylated and deaminated derivatives.

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of amphetamines in urine exceeds 1,000 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).

Amphetamine (AMP 500)

The Multi-Drug Rapid Test Cup yields a positive result when amphetamines in urine exceed500 ng/mL. See Amphetamine (AMP 1,000) for the summary.

Amphetamine (AMP 300)

The Multi-Drug Rapid Test Cup yields a positive result when amphetamines in urine exceed 300 ng/mL. See Amphetamine (AMP 1.000) for the summary.

Barbiturates (BAR 300)

Barbiturates are CNS depressants. They are used therapeutically as sedatives, hypnotics, and anticonvulsants barbiturates are almost always taken orally as capsules or tablets. The effects resemble those of intoxication with alcohol. Chronic use of barbiturates leads to tolerance and physical dependence.

Short-acting barbiturates taken at 400 mg/day for 2-3 months can produce a clinically significant degree of physical dependence. Withdrawal symptoms experienced during periods of drug abstinence can be severe enough to cause death.

Only a small amount (less than 5%) of most barbiturates are excreted unaltered in the urine.

The approximate detection time limits for barbiturates are:

Short acting (e.g. Secobarbital)	100 mg PO (oral)
Long acting (e.g. Phenobarbital)	400 mg PO (oral)

7 davs² D (oral) The Multi-Drug Rapid Test Cup yields a positive result when the concentration of

4.5 days

barbiturates in urine exceeds 300 ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for Barbiturate positive specimens.

Barbiturates (BAR 200)

The Multi-Drug Rapid Test Cup yields a positive result when barbiturates in urine exceed 200 ng/mL. See Barbiturates (BAR 300) for the summary.

Benzodiazepines (BZO 500)

Benzodiazepines are medications that are frequently prescribed for the symptomatic treatment of anxiety and sleep disorders. They produce their effects via specific receptors involving a neurochemical called gamma aminobutyric acid (GABA). Because they are safer and more effective, benzodiazepines have replaced barbiturates in the treatment of both anxiety and insomnia. Benzodiazepines are also used as sedatives before some surgical and medical procedures, and for the treatment of seizure disorders and alcohol withdrawal. Risk of physical dependence increases if benzodiazepines are taken regularly (e.g., daily) for more than a few months, especially at higher than normal doses. Stopping abruptly can bring on such symptoms as trouble sleeping, gastrointestinal upset, feeling unwell, loss of appetite, sweating, trembling, weakness, anxiety and changes in perception.

Only trace amounts (less than 1%) of most benzodiazepines are excreted unaltered in the urine; most of the concentration in urine is conjugated drug. The detection period for benzodiazepines in urine is 3-7 days.

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of benzodiazepines in urine exceeds 500 ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for benzodiazepine positive specimens.

Benzodiazepines (BZO 300)

The Multi-Drug Rapid Test Cup yields a positive result when benzodiazepines in urine exceed 300 ng/mL. See Benzodiazepines (BZO 500) for the summary.

Benzodiazepines (BZO 200)

The Multi-Drug Rapid Test Cup yields a positive result when benzodiazepines in urine exceed 200 ng/mL. See Benzodiazepines (BZO 500) for the summary.

Benzodiazepines (BZO 100)

The Multi-Drug Rapid Test Cup yields a positive result when benzodiazepines in urine exceed 100 ng/mL. See Benzodiazepines (BZO 500) for the summary.

Buprenorphine (BUP)

Buprenorphine is a potent analgesic often used in the treatment of opioid addiction. The drug is sold under the trade names Subutex™, Buprenex™ Temgesic™ and Suboxone™, which contain Buprenorphine HCl alone or in combination with Naloxone HCl. Therapeutically, Buprenorphine is used as a substitution treatment for opioid addicts. Substitution treatment is a form of medical care offered to opiate addicts (primarily heroin addicts) based on a similar or identical substance to the drug normally used. In substitution therapy, Buprenorphine is as effective as Methadone but demonstrates a lower level of physical dependence. Concentrations of free Buprenorphine and Norbuprenorphine in urine may be less than 1 ng/ml after therapeutic administration, but can range up to 20 ng/ml in abuse situations. The plasma half life of Buprenorphine is 2-4 hours.⁷While complete elimination of a single dose of the drug can take as long as 6 days, the window of detection for the parent drug in urine is thought to be approximately 3 days.

Substantial abuse of Buprenorphine has also been reported in many countries where various forms of the drug are available. The drug has been diverted from legitimate channels through theft, doctor shopping, and fraudulent prescriptions, and been abused via intravenous, sublingual, intranasal and inhalation routes. The Multi-Drug Rapid Test Cup yields a positive result when the Buprenorphine in urine exceeds 10 ng/mL.

Cocaine(COC 300)

Cocaine is a potent central nervous system stimulant and a local anesthetic. Initially, it brings about extreme energy and restlessness while gradually resulting in tremors, over-sensitivity and spasms. In large amounts, cocaine causes fever, unresponsiveness, difficulty in breathing and unconsciousness. Cocaine is often self-administered by nasal inhalation, intravenous injection and

free-base smoking. It is excreted in the urine in a short time primarily as benzoylecgonine.³⁴ Benzoylecgonine, a major metabolite of cocaine, has a longer biological half-life (5-8 hours) than cocaine (0.5-1.5 hours), and can generally be detected for 24-48 hours after cocaine exposure.⁴

TheMulti-Drug Rapid Test Cup yields a positive result when the concentration of benzoylecgonine in urine exceeds 300 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, ÚSA).

Cocaine (COC 100)

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of benzoylecgonine in urine exceeds 100 ng/mL. See Cocaine (COC 300) for the summary.

Marijuana (THC150)

THC (A9-tetrahydrocannabinol) is the primary active ingredient in cannabis (marijuana). When smoked or orally administered, THC produces euphoric effects. Users have impaired short-term memory and slowed learning. They may also experience transient episodes of confusion and anxiety. Long-term, relatively heavy use may be associated with behavioral disorders. The peak effect of marijuana administered by smoking occurs in 20-30 minutes and the duration is 90-120 minutes after one cigarette. Elevated levels of urinary metabolites are found within hours of exposure and remain detectable for 3-10 days after smoking. The main metabolite excreted in the urine is 11-nor-∆9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH).

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of THC-COOH in urine exceeds 150 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).

Marijuana (THC50)

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of THC-COOH in urine exceeds 50 ng/mL. See Marijuana (THC150)for the summary.

Marijuana (THC25)

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of THC-COOH in urine exceeds 25 ng/mL. See Marijuana (THC150) for the summary.

Methadone (MTD300)

Methadone is a narcotic analgesic prescribed for the management of moderate to severe pain and for the treatment of opiate dependence (heroin, Vicodin, Percocet, morphine). The pharmacology of oral methadone is very different from IV methadone. Oral methadone is partially stored in the liver for later use. IV methadone acts more like heroin. In most states you must go to a pain clinic or a methadone maintenance clinic to beprescribed methadone.

Methadone is a long acting pain reliever producing effects that last from twelve to forty-eight hours. Ideally, methadone frees the client from the pressures of obtaining illegal heroin, from the dangers of injection, and from the emotional roller coaster that most opiates produce. Methadone, if taken for long periods and at large doses, can lead to a very long withdrawal period. The withdrawals from methadone are more prolonged and troublesome than those provoked by heroin cessation, yet the substitution and phased removal of methadone is an acceptable method of detoxification for patients and therapists.

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of methadone in urine exceeds 300 ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for methadone positive specimens.

Methadone (MTD200)

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of methadone in urine exceeds 200 ng/mL. See Methadone (MTD300)for the summary.

Methamphetamine (MET 1,000)

Methamphetamine is an addictive stimulant drug that strongly activates certain systems in the brain. Methamphetamine is closely related chemically to Amphetamine, but the central nervous system effects of Methamphetamine are greater. Methamphetamine is made in illegal laboratories and has a high potential for abuse and dependence. The drug can be taken orally, injected, or inhaled. Acute higher doses lead to enhanced stimulation of the central nervous system and induce euphoria, alertness, reduced appetite, and a sense of increased energy and power. Cardiovascular responses to Methamphetamine include increased blood pressure and cardiac arrhythmias. More acute responses produce anxiety, paranoia, hallucinations, psychotic behavior, and eventually, depression and exhaustion.

The effects of Methamphetamine generally last 2-4 hours and the drug have a half-life of 9-24 hours in the body. Methamphetamine is excreted in the urine primarily as Amphetamine, and oxidized and deaminated derivatives. However, 10-20% of Methamphetamine is excreted unchanged. Thus, the presence of the parent compound in the urine indicates Methamphetamine use. Methamphetamine is generally detectable in the urine for 3-5 days, depending on urine pH level.

The Multi-Drug Rapid Test Cup is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Methamphetamine in urine. The Multi-Drug Rapid Test Cup yields a positive result when the Methamphetamine in urine exceeds 1,000ng/mL

Methamphetamine (MET 500)

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of Methamphetamine in urine exceeds 500 ng/mL. See Methamphetamine (MET1,000) for the summary.

Methamphetamine (MET 300)

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of Methamphetamine in urine exceeds 300 ng/mL. See Methamphetamine (MET1.000) for the summary.

Methylenedioxymethamphetamine (MDMA500)

Methylenedioxymethamphetamine (ecstasy) is a designer drug first synthesized in 1914 by a German drug company for the treatment of obesity.⁵ Those who take the drug frequently report adverse effects, such as increased muscle tension and sweating. MDMA is not clearly a stimulant, although it has, in common with amphetamine drugs, a capacity to increase blood pressure and heart rate. MDMA does produce some perceptual changes in the form of increased sensitivity to light, difficulty in focusing, and blurred vision in some users. Its mechanism of action is thought to be via release of the neurotransmitter serotonin. MDMA may also release dopamine, although the general opinion is that this is a secondary effect of the drug (Nichols and Oberlender, 1990). The most pervasive effect of MDMA, occurring in virtually all people who took a reasonable dose of the drug, was to produce a clenching of the jaws.

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of Methylenedioxymethamphetamine in urine exceeds 500 ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for Methylenedioxymethamphetamine positive specimens.

Methylenedioxymethamphetamine (MDMA1.000)

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of methylenedioxymethamphetamine in urine exceeds 1,000 ng/mL. See methylenedioxymethamphetamine (MDMA500) for the summary.

Morphine (MOP 300)

Opiate refers to any drug that is derived from the opium poppy, including the natural products, morphine and codeine, and the semi-synthetic drugs such as heroin. Opioid is more general, referring to any drug that acts on the opioid receptor.

Opioid analgesics comprise a large group of substances which control pain by depressing the CNS. Large doses of morphine can produce higher tolerance levels, physiological dependency in users, and may lead to substance abuse. Morphine is excreted unmetabolized, and is also the major metabolic product of codeine and heroin. Morphine is detectable in the urine for several days after an opiate dose.²

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of morphine in urine exceeds 300ng/mL.

Morphine (MOP 100)

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of morphine in urine exceeds 100 ng/mL. See Morphine (MOP300) for the summary.

Morphine/Opiate (OPI 2,000)

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of morphine in urine exceeds 2,000 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).1 See morphine (MOP 300) for summary.

Methaqualone (MQL)

Methaqualone (Quaalude, Sopor) is a quinazoline derivative that was first synthesized in 1951 and found clinically effective as a sedative and hypnotic in 1956.¹⁰ It soon gained popularity as a drug of abuse and in 1984 was removed from the US market due to extensive misuse. It is occasionally encountered in illicit form, and is also available in Europeon countries in combination with diphenhydramine (Mandrax). Methaqualone is extensively metabolized *in vivo* principally by hydroxylation at every possible position on the molecule. At least 12 metabolites have been identified in the urine.

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of Methagualone in urine exceeds 300 ng/mL.

Phencyclidine (PCP)

Phencyclidine, also known as PCP or Angel Dust, is a hallucinogen that was first marketed as a surgical anesthetic in the 1950's. It was removed from the market because patients receiving it became delirious and experienced hallucinations. PCP is used in powder, capsule, and tablet form. The powder is either snorted or smoked after mixing it with marijuana or vegetable matter. PCP is most commonly administered by inhalation but can be used intravenously, intra-nasally, and orally. After low doses, the user thinks and acts swiftly and experiences mood swings from euphoria to depression. Self-injurious behavior is one of the devastating effects of PCP.

PCP can be found in urine within 4 to 6 hours after use and will remain in urine for 7 to 14 days, depending on factors such as metabolic rate, user's age, weight, activity, and diet.6 PCP is excreted in the urine as an unchanged drug (4% to 19%) and conjugated metabolites (25% to 30%).

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of phencyclidine in urine exceeds 25 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).

Propoxyphene (PPX)

Propoxyphene (PPX) is a narcotic analgesic compound bearing structural similarity to methadone. As an analgesic, propoxyphene can be from 50-75% as potent as oral codeine. Darvocet™, one of the most common brand names for the drug, contains 50-100 mg of propoxyphene napsylate and 325-650 mg of acetaminophen. Peak plasma concentrations of propoxyphene are achieved from 1 to 2 hours post dose. In the case of overdose, propoxyphene blood concentrations can reach significantly higher levels.

In humans, propoxyphene is metabolized by N-demethylation to yield norpropoxyphene. Norpropoxyphene has a longer half-life (30 to 36 hours) than parent propoxyphene (6 to 12 hours). The accumulation of norpropoxyphene seen with repeated doses may be largely responsible for resultant toxicity.

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of Propoxyphene or Norpropoxyphene in urine exceeds 300 ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for propoxyphene positive specimens.

Tricyclic Antidepressants (TCA)

TCA (Tricyclic Antidepressants) are commonly used for the treatment of depressive disorders. TCA overdoses can result in profound CNS depression, cardiotoxicity and anticholinergic effects. TCA overdose is the most common cause of death from prescription drugs. TCAs are taken orally or sometimes by injection. TCAs are metabolized in the liver. Both TCAs and their metabolites are excreted in urine mostly in the form of metabolites for up to ten days.

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of tricyclic antidepressants in urine exceeds 1,000 ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for tricyclic antidepressant positive specimens.

Tramadol (TML)

Tramadol(TML) is a quasi-narcotic analgesic used in the treatment of moderate to severe pain. It is a synthetic analog of codeine, but has a low binding affinity to

the mu-opioid receptors. Large doses of tramadol can develop tolerance and physiological dependency and lead to its abuse. Tramadol is extensively metabolized after oral administration. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% is excreted as metabolites. The major pathways appear to be N- and O- demethylation, glucoronidation or sulfation in the liver.

The Multi-Drug Rapid Test Cup is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Tramadol in urine. The The Multi-Drug Rapid Test Cup yields a positive result when Tramadol in urine exceed 100 ng/mL.

Ketamine(KET1,000)

Ketamine is a dissociative anesthetic developed in 1963 to replace PCP (Phencyclidine). While Ketamine is still used in human anesthesia and veterinary medicine, it is becoming increasingly abused as a street drug. Ketamine is molecularly similar to PCP and thus creates similar effects including numbness, loss of coordination, sense of invulnerability, muscle rigidity, aggressive / violent behavior, slurred or blocked speech, exaggerated sense of strength, and a blank stare. There is depression of respiratory function but not of the central nervous system, and cardiovascular function is maintained. The effects of Ketamine generally last 4-6 hours following use. Ketamine is excreted in the urine as unchanged drug (2.3%) and metabolites (96.8%).¹⁰

The Multi-Drug Rapid Test Cup is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Ketamine in urine. The Multi-Drug Rapid Test Cup yields a positive result when Ketamine in urine exceeds 1,000ng/mL.

Ketamine (KET500)

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of Ketamine in urine exceeds 500 ng/mL. See Ketamine(KET1,000) for the summary.

Ketamine (KET300)

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of Ketamine in urine exceeds 300 ng/mL. See Ketamine(KET1,000) for the summary.

Ketamine (KET100)

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of Ketamine in urine exceeds 100 ng/mL. See Ketamine(KET1,000) for the summary.

Oxycodone (OXY)

Oxycodone is a semi-synthetic opioid with a structural similarity to codeine. The drug is manufactured by modifying thebaine, an alkaloid found in the opium poppy. Oxycodone, like all opiate agonists, provides pain relief by acting on opioid receptors in the spinal cord, brain, and possibly directly in the affected tissues. Oxycodone is prescribed for the relief of moderate to high pain under the well-known pharmaceutical trade names of OxyContin®, TylowB, Percodan® and Percocet® contain only small doses of oxycodone hydrochloride combined with other analgesics such as acetaminophen or aspirin, OxyContin consists solely of oxycodone hydrochloride in a time-release form. Oxycodone is known to metabolize by demethylation into oxymorphone and noroxycodone. In a 24-hour urine, 33-61% of a single, 5 mg oral dose is excreted with the primary constituents being unchanged drug (13-19%), conjugated drug (7-29%) and conjugated oxymorphone (13-14%). The window of detection for Oxycodone in urine is expected to be similar to that of other opioids such as morphine.

The Multi-Drug Rapid Test Cup is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Oxycodone in urine. The Multi-Drug Rapid Test Cup yields a positive result when Oxycodone in urine exceeds 100ng/mL.

Cotinine (COT 200)

Cotinine is the first-stage metabolite of nicotine, a toxic alkaloid that produces stimulation of the autonomic ganglia and central nervous system when in humans. Nicotine is a drug to which virtually every member of a tobacco-smoking society is exposed whether through direct contact or second-hand inhalation. In addition to tobacco, nicotine is also commercially available as the active ingredient in smoking replacement therapies such as nicotine gum, transdermal patches and nasal sprays.

In a 24-hour urine, approximately 5% of a nicotine dose is excreted as unchanged drug with 10% as cotinine and 35% as hydroxycotinine; the concentrations of other metabolites are believed to account for less than 5%. ¹⁰While cotinine is thought to be an inactive metabolite, it's elimination profile is more stable than that of nicotine which is largely urine pH dependent. As a result, cotinine is considered a good biological marker for determining nicotine use. The plasma half-life of nicotine is approximately 60 minutes following inhalation or parenteral administration. ¹¹Nicotine and cotinine are rapidly eliminated by the kidney; the window of detection for cotinine in urine at a cutoff level of 200 ng/mL is expected to be up to 2-3 days after nicotine use.

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of Cotinine in urine exceeds 200 ng/ml

Cotinine (COT 100)

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of Cotinine in urine exceeds 100 ng/mL. See Cotinine(COT200) for the summary.

2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP 300)

Methadone is an unusual drug in that its primary urinary metabolites (EDDP and EMDP) are cyclic in structure, making them very difficult to detect using immunoassays targeted to the native compound.¹⁰Exacerbating this problem, there is a subsection of the population classified as "extensive metabolizers" of methadone. In these individuals, a urine specimen may not contain enough parent methadone to yield a positive drug screen even if the individual is in compliance with their methadone maintenance. EDDP represents a better urine marker for methadone maintenance than unmetabolized methadone.

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of EDDP in urine exceeds 300 ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for EDDP positive specimens.

2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP 100)

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of EDDP in urine exceeds 100 ng/mL. See EDDP 300 for the summary.

Fentanyl (FYL20)

Fentanyl, belongs to powerful narcotics analgesics, and is a µ special opiates receptor stimulant. Fentanyl is one of the varieties that been listed in management of United Nations "Single Convention of narcotic drug in 1961". Among the opiates agents that under international control, fentanyl is one of the most commonly used to cure moderate to severe pain1. After continuous injection of fentanyl, the sufferer will have the performance of protracted opioid abstinence syndrome, such as ataxia and irritability etc2,3, which presents the addiction after taking fentanyl in a long time. Compared with drug addicts of amphetamine, drug addicts who take fentanyl mainly have got the possibility of higher infection rate of HIV, more dangerous injection behavior and more lifelong medication overdose 4.

The FYL Rapid Test Dipstick (Urine) is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of FYL in urine. The FYL Rapid Test Dipstick (Urine) yields a positive result when FYL in urine exceeds 20 ng/mL.

Fentanyl (FYL10)

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of Norfentanyl in urine exceeds 10 ng/mL. See FLY20for the summary.

Synthetic Marijuana (K2-50)

Synthetic Marijuana or K2 a psychoactive herbal and chemical product that when consumed, mimics the effects of Marijuana. It is best known by the brandnames K2 and Spice, both of which have largely become genericized trademarksused to refer to any synthetic Marijuana product. The studies suggest thatsynthetic marijuana intoxication is associated with acute psychosis, worsening ofpreviously stable psychotic disorders, and also may have the ability to trigger achronic (long-term) psychotic disorder among vulnerable individuals such asthose with a family history of mental illness.

Elevated levels of urinary metabolites are found within hours of exposure andremain detectable for 72 hours after smoking (depending on usage/dosage). As of March 1, 2011, five cannabinoids, JWH -018, JWH- 073, CP- 47, JWH- 200 and cannabicyclo hexanol are now illegal in the US because these substances have the potential to be extremely harmful and, therefore, pose an imminent hazard to the public safety.

The Multi-Drug Rapid Test Cup yields a positive result when the synthetic marijuana metabolite in urine exceeds 50ng/mL.

Synthetic Marijuana (K2-30)

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of the synthetic marijuana metabolite in urine exceeds 30ng/mL. 6-mono-aceto-morphine (6-MAM10)

6-Monoacetylmorphine (6-MAM) or 6-acetylmorphine (6-AM) is one of three active metabolites of heroin (diacetylmorphine), the others being morphine and the much less active 3-monoacetylmorphine (3-MAM). 6-MAM is rapidly created from heroin in the body, and then is either metabolized into morphine or excreted in the urine. 6-MAM remains in the urine for no more than 24 hours. So a urine specimen must be collected soon after the last heroin use, but the presence of 6-MAM guarantees that heroin was in fact used as recently as within the last day. 6-MAM is naturally found in the brain, but in such small quantities that detection of this compound in urine virtually guarantees that heroin has recently been consumed. The Multi-Drug Rapid Test Cup yields a positive result when the concentration of the 6-Monoacetylmorphine in urine exceeds 10ng/mL.

(±) 3, 4-Methylenedioxyamphetamine (MDA500)

3,4-Methylenedioxyamphetamine (MDA), also known as tenamfetamine (INN), or with the street name "Sally" or "Sass" or "Sass-a-frass", is a psychedelic and entactogenic drug of the phenethylamine and amphetamine chemical classes. It

is mainly used as a recreational drug, an entheogen, and a tool in use to supplement various types of practices for transcendence, including in meditation, psychonautics, and as an agent in psychedelic psychotherapy. It was first synthesized by G. Mannish and W. Jacobson in 1910. There are about 20 different synthetic routes described in the literature for its preparation.

Ethyl- β-D-Glucuronide(ETG500)

Ethyl Glucuronide (ETG) is a metabolite of ethyl alcohol which is formed in the body by glucuronidation following exposure to ethanol, such as by drinking alcoholic beverages. It is used as a biomarker to test for ethanol use and to monitor alcohol abstinence in situations where drinking is prohibited, such as in the military, in professional monitoring programs (health professionals, attorneys, airline pilots in recovery from addictions), in schools, in liver transplant clinics, or in recovering alcoholic patients. ETG can be measured in urine up to approximately 80 hours after ethanol is ingested. ETG is a more accurate indicator of the recent exposure to alcohol than measuring for the presence of ethanol itself.

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of Ethyl Glucuronide in urine exceeds 500 ng/ml

Ethyl-β-D-Glucuronide(ETG1,000)

The Multi-Drug Rapid Test Cup yields a positive result when the concentration of Ethyl Glucuronide in urine exceeds 1,000 ng/ml. See Ethyl-β-D-Glucuronide (ETG500) for the summary

WHAT IS ADULTERATION

Adulteration is the tampering of a urine specimen with the intention of altering the test results. The use of adulterants can cause false negative results in drug tests by either interfering with the screening test and/or destroying the drugs present in the urine. Dilution may also be employed in an attempt to produce false negative drug test results.

One of the best ways to test for adulteration or dilution is to determine certain urinary characteristics such as pH, specific gravity and creatinine and to detect the presence of oxidants/PCC, nitrites or glutaraldehyde in urine.

Oxidants/PCC (Pyridiniumchlorochromate) tests for the presence of oxidizing agents such as bleach and hydrogen peroxide. Pyridiniumchlorochromate (sold under the brand name UrineLuck) is a commonly used adulterant.8 Normal human urine should not contain oxidants of PCC.

Specific gravity tests for sample dilution. The normal range is from 1.003 to 1.030. Values outside this range may be the result of specimen dilution or adulteration.

pHtests for the presence of acidic or alkaline adulterants in urine. Normal pH levels should be in the range of 4.0 to 9.0. Values outside of this range may indicate the sample has been altered.

Nitritetests for commonly used commercial adulterants such as Klear and Whizzies. They work by oxidizing the major cannabinoid metabolite THC-COOH.9 Normal urine should contain no trace of nitrite. Positive results generally indicate the presence of an adulterant.

Glutaraldehydetests for the presence of an aldehyde. Adulterants such as UrinAid and Clear Choice contain glutaraldehvde which may cause false negative results by disrupting the enzyme used in some immunoassay tests.9 Glutaraldehyde is not normally found in urine; therefore, detection of glutaraldehyde in a urine specimen is generally an indicator of adulteration.

Creatinine is a waste product of creatine; an amino-acid contained in muscle tissue and found in urine.2 A person may attempt to foil a test by drinking excessive amounts of water or diuretics such as herbal teas to " flush" the system. Creatinine and specific gravity are two ways to check for dilution and flushing, which are the most common mechanisms used in an attempt to circumvent drug testing. Low Creatinine and specific gravity levels may indicate dilute urine. The absence of Creatinine (<5 mg/dl) is indicative of a specimen not consistent with human urine.

[PRINCIPLE]

During testing, a urine specimen migrates upward by capillary action. A drug, if present in the urine specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test region of the specific drug dipstick. The presence of drug above the cut-off concentration will saturate all the binding sites of the antibody. Therefore, the colored line will not form in the test region.

A drug-positive urine specimen will not generate a colored line in the specific test region of the dipstick because of drug competition, while a drug-negative urine specimen will generate a line in the test region because of the absence of drug competition.

To serve as a procedural control, a colored line will always appear at the control region, indicating that proper volume of specimen has been added and membrane wicking has occurred.

[REAGENTS]

Each test line contains anti-drug mouse monoclonal antibody and corresponding drug-protein conjugates. The control line contains goat anti-rabbit IgG polyclonal antibodies and rabbit IgG.

[S.V.T REAGENTS]

Adulteration Pad	Reactive indicator	Buffers and non-reactive ingredients
Creatinine	0.04%	99.95%
Nitrite	0.07%	99.94%
Glutaraldehyde	0.02%	99.97%
pН	0.06%	99.94%
Specific Gravity	0.25%	99.78%
Oxidants / PCC	0.36%	99.70%

[PRECAUTIONS]

- For healthcare professionals including professionals at point of care sites.
- Immunoassay for invitro diagnostic use only. The test Panel should remain in the sealed pouch until use.
- All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent.
- The used test Panel should be discarded according to federal, state and local regulations.

[STORAGE AND STABILITY]

Store as packaged in the sealed pouch at 2-30°C. The test is stable through the expiration date printed on the sealed pouch. The test Panels must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date.

[SPECIMEN COLLECTION AND PREPARATION]

Urine Assay

The urine specimen should be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be centrifuged, filtered, or allowed to settle to obtain a clear specimen for testing.

Specimen Storage


Urine specimens may be stored at 2-8°C for up to 48 hours prior to testing. For prolonged storage, specimens may be frozen and stored below -20°C. Frozen specimens should be thawed and mixed well before testing. When testing cards with S.V.T. storage of urine specimens should not exceed 2 hours at room temperature or 4 hours refrigerated prior to testing. (MATERIALS)

- Materials Provided
 - Package insert
- Security seal labels Adulteration Color Chart (when applicable) Materials Required But Not Provided
- Specimen collection container timer
- [DIRECTIONS FOR USE]

Cup

Allow the test, urine specimen, and/or controls to reach room temperature (15-30°C) prior to testing.

- 1. Bring the pouch to room temperature before opening it. Remove the cup from the sealed pouch and use it within one hour.
- 2. Donor provides specimen.
- 3. Technician replaces and secures cap while the cup is on a flat surface. 4. Technician dates and initials the security seal and attaches the security seal over the cup cap
- Technician peels off label to reveal adulteration strip(s), if applicable.
- 6. Technician peels off the label on the multi-drug test card to view results.
- 7. Read the adulteration strips between 3-5 minutes (when applicable) compare the colors on the adulteration pads to the enclosed color chart. If the specimen indicates adulteration, refer to your Drug Free Policy for guidelines on adulterated specimens. We recommend not to interpret the drug test results and either retest the urine or collect another specimen.



8. The drug strip result should be read at 5 minutes. Results may be stable up to 1 hour after test initiation.

(INTERPRETATION OF RESULTS)

(Please refer to the illustration above)

NEGATIVE:* A colored line appears in the Control region (C) and colored lines appears in the Test region (T). This negative result means that the concentrations in the urine sample are below the designated cut-off levels for a particular drug tested.

*NOTE: The shade of the colored lines(s) in the Test region (T) may vary. The result should be considered negative whenever there is even a faint line.

POSITIVE: A colored line appears in the Control region (C) and NO line appears in the Test region (T). The positive result means that the drug concentration in the urine sample is greater than the designated cut-off for a specific drug.

INVALID: No line appears in the Control region (C). Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for Control line failure. Read the directions again and repeat the test with a new test card. If the result is still invalid, contact your manufacturer. **(S.V.T/ ADULTERATION INTERPRETATION)**

(Please refer to the color chart)

Semi Quantitative results are obtained by visually comparing the reacted color blocks on the strip to the printed color blocks on the color chart. No instrumentation is required.

[QUALITY CONTROL]

A procedural control is included in the test. A line appearing in the control region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique. Control standards are not supplied with this kit. However, it is recommended that positive and negative controls be tested as good laboratory practice to confirm the test procedure and to verify proper test performance.

[LIMITATIONS]

- 1. The Multi-Drug Rapid Test Cup provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method.
- 2. There is a possibility that technical or procedural errors, as well as interfering substances in the urine specimen may cause erroneous results.
- 3. Adulterants, such as bleach and/or alum, in urine specimens may produce erroneous results regardless of the analytical method used. If adulteration is suspected, the test should be repeated with another urine specimen.
- 4. A positive result does not indicate level or intoxication, administration route or concentration in urine.
- 5. A negative result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the cut-off level of the
- 6. This test does not distinguish between drugs of abuse and certain medications.

7. A positive test result may be obtained from certain foods or food supplements. **S.V.T/ ADULTERATION LIMITATIONS**

- 1. The adulteration tests included with the product are meant to aid in the determination of abnormal specimens. While comprehensive, these tests are not meant to be an "all-inclusive" representation of possible adulterants.
- 2. Oxidants/PCC: Normal human urine should not contain oxidants or PCC. The presence of high levels of antioxidants in the specimen, such as ascorbic acid, may result in false negative results for the oxidants/PCC pad.
- Specific Gravity: Elevated levels of protein in urine may cause abnormally high specific gravity values.
- 4. Nitrite: Nitrite is not a normal component of human urine. However, nitrite found in urine may indicate urinary tract infections or bacterial infections. Nitrite levels of > 20 mg/dL may produce false positive glutaraldehyde results.
- 5. Glutaraldehyde: is not normally found in urine. However certain metabolic abnormalities such as ketoacidosis (fasting, uncontrolled diabetes or high protein diets) may interfere with the test results.
- 6. Creatinine: Normal Creatinine levels are between 20 and 350 mg/dL. Under rare conditions, certain kidney diseases may show dilute urine.

EXPECTED VALUES

The negative result indicates that the drug concentration is below the detectable level. Positive result means the concentration of drug is above the detectable level

[PERFORMANCE CHARACTERISTICS]

Accuracy

A side-by-side comparison was conducted using the Multi-Drug Rapid Test Cup and commercially available drug rapid tests. Testing was performed on approximately 250 specimens per drug type previously collected from subjects presenting for Drug Screen Testing. Presumptive positive results were confirmed by GC/MS

	thod apid Test Cup	GC/ Positive	Negative	% agreement with GC/MS
AMP	Positive	103	3	98.1%
1,000	Negative	2	142	97.9%
AMP	Positive	110	2	99.1%
500	Negative	1	137	98.6%
AMP	Positive	116	2	99.1%
300	Negative	1	131	98.5%
BAR	Positive	98	2	96.1%
300	Negative	4	146	98.6%
BAR	Positive	101	3	95.3%
200	Negative	5	141	97.9%
BZO	Positive	112	3	98.2%
500	Negative	2	133	97.8%
BZO	Positive	121	1	98.4%
300	Negative	2	126	99.2%
BZO	Positive	127	2	99.2%
200	Negative	1	120	98.4%
BZO	Positive	128	3	99.2%
100	Negative	1	118	97.5%
BUP	Positive	105	0	99.1%
	Negative	1	144	>99.9%
COC	Positive	111	3	98.2%
300	Negative	2	134	97.8%
COC	Positive	117	4	99.2%
100	Negative	1	128	97.0%
THC	Positive	86	4	94.5%
150	Negative	5	155	97.5%
THC	Positive	92	3	97.9%
50	Negative	2	153	98.1%
THC	Positive	95	4	96.9%
25	Negative	3	148	97.4%
MTD	Positive	89	2	98.9%
300	Negative	1	158	98.8%
MTD	Positive	91	2	98.7%
200	Negative	1	156	98.7%
MET	Positive	76	5	96.2%
1,000	Negative	3	166	97.1%
MET	Positive	83	5	97.6%
500	Negative	2	160	97.0%
MET 300	Positive	88	4	97.8%
	Negative	99	156	97.5%
MDMA 1,000	Positive Negative	2	148	98.0% 99.3%
MDMA	Positive	102	1	98.1%
500	Negative	2	145	99.3%
MOP	Positive	95	7	95.0%
300	Negative	5	143	95.3%
MOP	Positive	98	5	97.0%
100	Negative	3	144	96.6%
	Positive	79	11	89.8%
MQL	Negative	9	151	93.2%
0.01	Positive	117	8	96.7%
OPI	Negative	4	121	93.8%
000	Positive	85	5	92.4%
PCP	Negative	7	153	96.8%
DBY	Positive	97	9	96.0%
PPX	Negative	4	140	94.0%
TC A	Positive	91	13	94.8%
TCA	Negative	5	141	91.6%
TM	Positive	82	12	88.2%
TML	Negative	11	145	92.4%
KET	Positive	77	3	97.5%
1,000	Negative	2	168	98.2%
KET	Positive	81	3	97.6%
500	Negative	2	164	98.2%
KET	Positive	89	4	96.7%
300	Negative	3	154	97.5%
KET	Positive	97	4	96.0%
100	Negative	4	145	97.3%
OXY	Positive	84	1	97.7%
100	Negative	2	163	99.4%
COT	Positive	88	4	96.7%
200	Negative	3	155	97.5%
COT	Positive	93	3	97.9%
100	Negative	2	152	98.1%
EDDP	Positive	92	1	97.9%
300	Negative	2	155	99.4%
EDDP	Positive	95	5	96.9%
100	Negative	3	147	96.7%
FYL	Positive	79	1	98.8%
20	Negative	1	169	99.4%
FYL	Positive	80	1	98.8%
10	Negative	1	168	99.4%
K2-50	Positive	78	3	97.5%
	Negative	2	167	98.2%

GC/MS

Method

	Meth	od						201	MS				-					
Multi-Dru			Test Cup)		Posi	tive	5U/		Ne	gati	ve	- %	agr	eemer	nt wi	th G	C/MS
K2-30			Positive			82	2				2					7.6%		
			Negative Positive	•		2				1	2		_			8.8% 3.9%		
6-MAM1	0		Negative			1				154			-	98.7%				
MDA500)		Positive			10					3			98.1%				
			Negative Positive			2				1	142		_	97.9% 97.6%				
ETG500)		Negative			2				1	164		-			9.4%		
ETG1,00	0		Positive			81					1					5.3%		
,	-		Negative %	A 0	ro	4 164 reement with Commercial Ki					Ki+	99.4%						
	AN	۱P	AMP	AM		BAR			BZ			BZO	BZC		BZO		15	COC
	1,0	00	500	30		300	20	00	50			300	200		100	BI	JP	300
Positive Agreement	>99		>99.9%	>99 %	.9	>99.9	% >99		>99	.9%	>	99.9 %	>99.9	%	>99.9 %	>99	.9%	>99.9 %
Negative	>99	9.9	>99.9%	>99		>99.9	>99	9.9	~ 00	.9%	>	99.9	>99.9	0/ 2	>99.9	~ 00	.9%	>99.9
Agreement	%		>99.9%	%		>99.9	9		>99	.9%		%	>99.9	· · ·	%	>99	.9%	%
Total Results	s >99		>99.9%	>99 %	.9	>99.9	% >99		>99	.9%		99.9 %	>99.9	%	>99.9 %	>99	.9%	>99.9 %
		-		,,,														
	CO 100		THC 150	THC 50	;	THC 25	MT 30		MT 20			IET 000	MET 500		MET 300		MA 000	MDMA 500
Positive					~			-		-				~				
Agreement	>99.9	}% :	>99.9%	>99.9	%>	>99.9%	6 > 99.	9%	>99.	9%	>99	9.9%	>99.9	%>	99.9%	>99	.9%	>99.9%
Negative Agreement	>99.9	9%	>99.9%	>99.9	%	>99.9%	6>99.	9%	>99.	9%	>99	9.9%	>99.9	%>	99.9%	>99	.9%	>99.9%
Total	>99.9	20/	>99.9%	>99.9	0/ 5	>99.9%	6>99.	00/	>99.	00/	~ 00	9.9%	>99.9	0/~	99.9%	- 00	.9%	>99.9%
Results	>99.5	970	>99.9%	>99.9	70	>99.97	°>99.	9%	>99.	9%	>9:	9.9%	>99.9	70>3	99.9%	>99	.9%	>99.97
	МС	D	MOP		_			1		-			KE	r I	KET	L K	ET	KET
	30		100	MQ	L	OPI	PCP	1	PPX	Т	CA	TML	1,00		500		00	100
Positive	>99.	9%	>99.9%	>99.9	9%	*	>99.9	%>	99.99	%	*	*	>99.9	9%>	99.9%	>99	9.9%	>99.99
Agreement Negative						*		-			*	*						
Agreement	>99.	9%	>99.9%	>99.9	9%		>99.9	%>	99.99	%	*		>99.9	9%>	99.9%	>99	9.9%	>99.99
Total Results	s>99.	9%	>99.9%	>99.9	9%	*	>99.9	%>	99.99	%	*	*	>99.9	9%>	99.9%	>99	9.9%	>99.99
					_						-	1/2	1		1			
	OXY		OT CO 00 100			EDDF 100	20 FYL		FYL 10	K 5		K2 30		1AM 0	MDA 500		ETG 500	ETG 1,00
Positive	*	-	* *	,		*	*	T	*	,	,	*	_	*	*		*	*
Agreement Negative		-		_				_					_			_		
Agreement	*		* *	*		*	*		*	•	,	*		*	*		*	*
Total Results	*		* *	*		*	*		*	,	r	*		*	*		*	*
* Not	te: B	as	ed on (GC/I	ИS	data	a inst	ea	d of	С	om	mer	cial I	<it.< td=""><td></td><td></td><td></td><td></td></it.<>				
							Prec											
A study w	as co	ono	ducted	at th	nre	e ho	spita	ls I	by la	ayp	er	sons	s usir	ng t	hree	dif	fere	nt lot
of product	t to An											n ru nens						
precision. concentra			dentica f + 50%		ar d +										ainin		drug	
at each sit										. .,				a, 2				
AM <u>PHET</u>	AMIN	١E	(AMP	1,00)Ő))												_
			tamine			np			Site			-	Site I		_	Site		
	con	_	ng/mL)			si 1			- 0	+	_	- 10		+	- 10	0	+	_
		50				1	-		0	(1(0	10		0	\neg
		75				1	-		9	1		8	-	2	g	-	1	
			250			1			1	ę		2	_	8	2		8	
		1,5	500			1	-		0	_	0	0	_	10	0		10)
AMPHET	AMIN			500)													
			tamine			n p			Site			<u> </u>	Site I		_	Site		
	con	_	ng/mL)			si 1			-	+		-		+	-		+	
	0 250					1	-		0	(_	10	_	0	10		0	_
	250 375					1			9	1		9		1	g		1	-
			25			1			2	8		1		9	2		8	
		75	50			1			0		0	0	1	10	0		10)
AMPHET	AMIN	١E	(AMP	300)													
			tamine			np			Site			<u> </u>	Site I			Site	-	
	con	c. (ng/mL)			si	ie		-	+	ł	-	-	+	-		+	

10

10

10

10

10

0

150

225

375

450

10

10 0 10 0

8

2

0

0 10 0

2 8 2 8 2

8 2 8 2 8

10

0 10 0 10

10

10 0

BARBITURATES (BAR 300)

BARBITURATES (BAR					-		-
Secobarbital	n per	Sit	e A		e B	Site	
conc. (ng/mL)	site 10	- 10	+	-	+	-	+
0 150	10	10 10	0	10 10	0	10 10	0
225	10	9	1	8	2	9	1
375	10	2	8	0	9	2	8
450	10	0	10	0	10	0	10
BARBITURATES (BAR				. ~			
Secobarbital	n per	Sit	e A	Sit	e B	Site	еC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
100	10	10	0	10	0	10	0
150	10	9	1	9	1	9	1
250	10	1	9	1	9	1	9
300 BENZODIAZEPINES (B2	10	0	10	0	10	0	10
		Sit	e A	Sit	e B	Site	۰C
Oxazepam conc. (ng/mL)	n per site	-	1	-	1	-	1
0	10	- 10	+	- 10	+	- 10	+ 0
250	10	10	0	10	0	10	0
375	10	8	2	9	1	8	2
625	10	1	9	2	8	1	9
750	10	0	10	0	10	0	10
BENZODIAZEPINES (B	ZO 300)						
Oxazepam	n per		e A		eВ	Site	
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225 375	10 10	9 1	1 9	9 1	1 9	9 1	1
450	10	0	9 10	0	9 10	0	9 10
BENZODIAZEPINES (B		5	.0				10
Oxazepam	n per	Sit	e A	Sit	e B	Site	e C
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
100	10	10	0	10	0	10	0
150	10	9	1	8	2	9	1
250	10	1	9	1	9	2	8
	10	0	10	0	10	0	10
BENZODIAZEPINES (B2		0.4	e A	Sit	٥B	Site	<u>م</u> ۲
Oxazepam conc. (ng/mL)	n per site	-	е А +	- 510	ев +	-	e C +
	0110		0	10	0		+ 0
0	10	10				10	
0 50	10	10 10				10 10	0
0 50 75	10 10 10	10 10 9	0	10 8	0	10 10 7	0
50	10	10	0	10	0	10	
50 75 125 150	10 10 10 10	10 9	0 1	10 8	0 2	10 7	3 8
50 75 125 150	10 10 10 10	10 9 1 0	0 1 9 10	10 8 1 0	0 2 9 10	10 7 2 0	3 8 10
50 75 125 50 BUPRENORPHINE (BUI Buprenorphine	10 10 10 10 P) n per	10 9 1 0 Sit	0 1 9 10 e A	10 8 1 0 Site	0 2 9 10 e B	10 7 2 0 Site	3 8 10 e C
50 75 125 30 BUPRENORPHINE (BUI Buprenorphine conc. (ng/mL)	10 10 10 10 P) n per site	10 9 1 0 Sit	0 1 9 10 e A +	10 8 1 0 Site	0 2 9 10 e B +	10 7 2 0 Site	3 8 10 e C +
50 75 125 50 BUPRENORPHINE (BUI Buprenorphine conc. (ng/mL) 0	10 10 10 10 P) n per site 10	10 9 1 0 Sit - 10	0 1 9 10 e A + 0	10 8 1 0 Situ - 10	0 2 9 10 e B + 0	10 7 2 0 Site -	3 8 10 e C + 0
50 75 125 30 30 75 80 75 80 75 80 75 80 75 80 75 80 75 80 75 80 75 80 75 80 75 80 75 80 75 80 75 80 75 80 80 80 80 80 80 80 80 80 80 80 80 80	10 10 10 10 P) n per site 10 10	10 9 1 0 Sit - 10 10	0 1 9 10 e A + 0 0	10 8 1 0 Situ - 10 10	0 2 9 10 e B + 0 0	10 7 2 0 Site - 10 10	3 8 10 e C + 0 0
50 75 125 30 30 75 30 7.5	10 10 10 10 P) n per site 10 10 10	10 9 1 0 Sit - 10 10 9	0 1 9 10 e A + 0 0 1	10 8 1 0 Situ - 10 10 9	0 2 9 10 e B + 0 0 1	10 7 2 0 Site - 10 10 8	3 8 10 e C + 0 0 2
50 75 125 30 PRENORPHINE (BUI Buprenorphine conc. (ng/mL) 0 5 7.5 12.5	10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	10 9 1 0 Sitt - 10 10 9 1	0 1 9 10 e A + 0 0 1 9	10 8 1 0 Situ - 10 10 9 1	0 2 9 10 • B + 0 0 1 9	10 7 2 0 Situ - 10 10 8 1	3 8 10 e C + 0 0 2 9
50 75 125 150 BUPRENORPHINE (BUI Buprenorphine conc. (ng/mL) 0 5 7.5 7.5 12.5 15	10 10 10 10 P) n per site 10 10 10	10 9 1 0 Sit - 10 10 9	0 1 9 10 e A + 0 0 1	10 8 1 0 Situ - 10 10 9	0 2 9 10 e B + 0 0 1	10 7 2 0 Site - 10 10 8	3 8 10 e C + 0 0 2
50 75 125 150 BUPRENORPHINE (BUI Buprenorphine conc. (ng/mL) 0 5 7.5 7.5 12.5 15	10 10 10 10 P) 10 P) 10 10 10 10	10 9 1 0 Sitt - 10 10 9 1 0	0 1 9 10 e A + 0 0 1 9	10 8 1 0 Situ - 10 10 9 1 0	0 2 9 10 • B + 0 0 1 9	10 7 2 0 Situ - 10 10 8 1	3 8 10 e C + 0 0 2 9 10
50 75 125 150 3UPRENORPHINE (BUI Buprenorphine conc. (ng/mL) 0 5 7.5 7.5 12.5 15 COCAINE (COC 300)	10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	10 9 1 0 Sitt - 10 10 9 1 0	0 1 9 10 e A + 0 0 1 9 10	10 8 1 0 Situ - 10 10 9 1 0	0 2 9 10 e B + 0 0 1 9 10	10 7 2 0 Site - 10 10 8 1 0	3 8 10 e C + 0 0 2 9 10
50 75 125 50 BUPRENORPHINE (BUI Buprenorphine conc. (ng/mL) 0 5 7.5 12.5 15 COCAINE (COC 300) Benzoylecgonine	10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	10 9 1 0 Sitt - 10 10 9 1 0	0 1 9 10 e A + 0 0 1 9 10 e A	10 8 1 0 Situ - 10 10 9 1 0	0 2 9 10 e B + 0 0 1 9 10 e B	10 7 2 0 Site - 10 10 8 1 0	3 8 10 e C + 0 0 2 9 9 10 e C
50 75 125 150 3UPRENORPHINE (BUI Buprenorphine conc. (ng/mL) 0 5 7.5 12.5 15 COCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150	10 10	10 9 1 0 10 10 9 9 1 0 0 Sitt - 10 10	0 1 9 10 e A + 0 0 1 9 10 e A + 0 0	10 8 1 0 5 10 10 9 9 1 0 5 11 0 0 5 11 0 10	0 2 9 10 • B + 0 0 1 9 10 • B • C	10 7 2 0 5ite - 10 10 8 8 1 0 0 5ite - 10 10	3 8 10 e C 4 9 10 2 9 10 0 0 0 0
50 75 125 150 BUPRENORPHINE (BUI Buprenorphine conc. (ng/mL) 0 5 7.5 12.5 15 COCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150 225	10 10	10 9 1 0 5 10 10 9 1 0 5 8 10 10 9 9	0 1 9 10 e A + 0 0 1 9 10 e A + 0 0 1 0 10 1 9 10 10 1 10 10 10 10 10 10 10	10 8 1 0 5 10 10 9 1 0 5 10 10 9 9	0 2 9 10 e B + 0 0 1 9 10 e B + 0 0 0 1	10 7 2 0 10 10 10 8 1 0 5 ite - 10 10 9	3 8 10 e C + + 0 0 2 9 9 10 e C + 0 0 0 1
50 75 125 50 BUPRENORPHINE (BUI Buprenorphine conc. (ng/mL) 0 5 7.5 12.5 15 COCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150 225 375	10 10	10 9 1 0 5 10 10 9 1 0 5 8 10 10 9 1	0 1 9 10 e A + 0 0 1 9 10 e A + 0 0 1 9 10 e A - - - - - - - - - - - - -	10 8 1 0 5 10 10 9 1 0 5 8 10 10 9 1	0 2 9 10 e B + 0 0 1 9 10 e B + 0 0 0 1 9 9	10 7 2 0 5 10 10 8 1 0 8 1 0 5 10 10 9 1	3 8 10 e C 4 9 9 10 2 9 9 10 0 0 1 0 0 1 9 9
50 75 125 150 3UPRENORPHINE (BUI Buprenorphine conc. (ng/mL) 0 5 7.5 12.5 15 COCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150 225 375 450	10 10	10 9 1 0 5 10 10 9 1 0 5 8 10 10 9 9	0 1 9 10 e A + 0 0 1 9 10 e A + 0 0 1 0 1 0 1 0 1 0 1 1 0 1 1 0 1 0 1 1 0 1 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1	10 8 1 0 5 10 10 9 1 0 5 10 10 9 9	0 2 9 10 e B + 0 0 1 9 10 e B + 0 0 0 1	10 7 2 0 10 10 10 8 1 0 5 ite - 10 10 9	3 8 10 e C 4 9 9 10 2 9 9 10 0 0 1 0 0 1 9 9
50 75 125 150 3UPRENORPHINE (BUI Buprenorphine conc. (ng/mL) 0 5 7.5 12.5 15 COCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150 225 375 450 COCAINE (COC 100)	10 10	10 9 1 0 10 10 9 1 0 0 5 it - 0 0 10 10 9 1 10 0 9	0 1 9 10 e A + 0 0 1 9 10 e A + 0 0 10 e A + 10 9 10 10 10 10 10 10 10 10 10 10	10 8 1 0 Sitt - 10 10 9 1 0 Sitt - 10 10 9 1 0 - - 10 0 - - - - - - - - - - - - -	0 2 9 10 e B + 0 10 9 10 e B + 0 0 10 9 10	10 7 2 0 5 10 10 8 1 0 0 5 10 10 10 9 1 0	3 8 10 e C 9 9 10 2 9 9 10 0 0 10 0 1 9 9 10 0 0 1 1 9 9 10
50 75 125 150 BUPRENORPHINE (BUI Buprenorphine conc. (ng/mL) 0 5 7.5 12.5 15 COCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150 225 375 450 COCAINE (COC 100) Benzoylecgonine	10 10	10 9 1 0 10 10 9 1 0 5 itt - 10 10 10 9 1 10 0 5 itt - 5 5 itt - 5 5 5 5 5 10 9 1 0 9 1 1 0 10 10 10 10 10 10 10 10 10 10 10	0 1 9 10 e A + 0 1 9 10 e A + 0 0 1 9 10 e A + 0 0 1 9 10 e A + 0 0 10 e A + 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0	10 8 1 0 Situ - 10 10 9 1 0 Situ - 10 10 0 Situ - 5 10 10 0 Situ - 5 10 10 10 10 10 10 5 10 10 10 10 10 10 10 10 10 10	0 2 9 10 e B + 0 10 9 10 e B + 0 0 1 9 10 e B + 0 0 1 10 e B + 10 9 10 0 10 9 10 9 9 10	10 7 2 0 10 10 8 1 0 5 10 10 10 9 1 0 0 5 itte 5 5	3 8 10 e C 2 9 9 10 2 2 9 9 10 0 0 1 1 9 9 10 0 0 1 1 9 9 10 0 0 0
50 75 125 150 Buprenorphine conc. (ng/mL) 0 7.5 7.5 12.5 COCAINE (COC 300) Benzoylegonine conc. (ng/mL) 0 150 225 375 COCAINE (COC 100) Benzoylegonine conc. (ng/mL)	10 10	10 9 1 0 10 10 9 1 0 5 itt - 10 10 9 1 0 9 1 0 5 itt - 5 10 0 9 1 0 5 10 - 10 9 10 - 10 9 10 - 10 - 10 - 10 -	0 1 9 10 e A + 0 0 1 9 10 e A + 0 0 1 9 10 e A + 0 0 1 9 10 e A + 10 0 0 10 0 0 10 0 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0	10 8 1 0 5 10 9 1 0 5 10 10 10 9 1 0 9 1 0 5 11 0 9 5 1 0 5 11 0 9 1 0 5 11 0 10 10 10 10 10 10 10 10 10 10 10 1	0 2 9 10 e B + 0 0 10 9 10 0 0 10 9 10 0 0 1 9 10 0 0 1 9 10 0 0 10 9 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 0	10 7 2 0 5itt - 10 10 8 1 0 5itt - 10 10 9 1 0 5 1 0 5 5 1 0 9 1 0 0 5 1 0 0 9 1 0 0 5 10 10 10 10 10 10 10 10 10 10 10 10 10	3 8 10 e C + 9 10 2 9 9 10 0 2 9 9 10 0 1 1 9 9 10 0 0 1 1 9 9 10 0 0 2 9 9 10 0 10 10 10 10 10 10 10 10 10 10 10 1
50 75 125 150 Buprenorphine (BUI conc. (ng/mL) 0 5 7.5 12.5 15 COCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150 225 375 450 COCAINE (COC 100) Benzoylecgonine 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	10 10	10 9 1 0 5it 10 9 1 0 9 1 0 9 1 0 9 1 0 9 1 1 0 9 1 1 0 10	0 1 9 10 e A + 0 0 1 9 10 e A + 0 0 1 9 10 e A + 0 0 1 9 10 e A + 0 0 10 10 e A + 0 0 0 10 10 10 10 10 10 10 1	10 8 1 0 Sith - 10 9 1 0 Sith - 10 10 9 1 0 Sith - 10 10 9 1 10 9 1 10 9 1 10 10 9 11 10 9 11 10 10 10 10 10 10 10 10 10	0 2 9 10 8 8 + 0 0 1 9 10 8 8 + 0 0 1 9 10 8 8 + 0 0 0 1 9 10	10 7 2 0 10 10 8 1 10 10 9 1 10 10 9 1 10 0 5 11 0	3 8 10 0 2 9 9 10 2 9 9 10 2 9 9 10 0 0 1 1 9 9 10 0 0 0 1 1 9 9 10 0 0 2 9 9 10 0 0 2 9 9 10 0 0 0 2 9 9 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
50 75 125 150 Buprenorphine conc. (ng/mL) 0 5 7.5 12.5 15 COCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150 2255 375 450 COCAINE (COC 100) Benzoylecgonine conc. (ng/mL) 0 50	10 10	10 9 1 0 5it 10 10 9 1 0 5it 10 9 10 10 10 9 10 10 10	0 1 9 10 e A + 0 0 1 9 10 e A + + 0 0 10 0 10 e A + + 0 0 0 10 0 0 10 0 0 0 10 0 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0	10 8 1 - 10 10 10 9 1 0 5itt - 10 10 9 10 10 10 10 10 10 10 10 10 10	0 2 9 10 10 0 1 10 0 1 10 0 1 10 0 1 10 0 1 10 0 1 10 0 10 0 10 1	10 7 2 0 10 10 10 8 8 1 0 0 10 10 9 9 1 0 0 5 8 10 10 10 10 10 10	3 8 10 0 2 9 9 10 2 9 9 10 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0
50 75 125 150 BUPRENORPHINE (BUI Buprenorphine conc. (ng/mL) 0 5 7.5 12.5 15 COCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150 225 375 450 COCAINE (COC 100) Benzoylecgonine conc. (ng/mL) 0 0	10 10	10 9 1 0 5it 10 9 1 0 9 1 0 9 1 0 9 1 0 9 1 1 0 9 1 1 0 10	0 1 9 10 e A + 0 0 1 9 10 e A + 0 0 1 9 10 e A + 0 0 1 9 10 e A + 0 0 10 10 e A + 0 0 0 10 10 10 10 10 10 10 1	10 8 1 0 Sith - 10 9 1 0 Sith - 10 10 9 1 0 Sith - 10 10 9 1 0 Sith - - 10 - - - - - - - - - - - - -	0 2 9 10 8 8 + 0 0 1 9 10 8 8 + 0 0 1 9 10 8 8 + 0 0 0 1 9 10	10 7 2 0 10 10 8 1 10 10 9 1 10 10 9 1 10 0 5 11 0	3 8 10 0 2 9 9 10 2 9 9 10 2 9 9 10 0 0 1 1 9 9 10 0 0 0 1 1 9 9 10 0 0 2 9 9 10 0 0 2 9 9 10 0 0 0 2 9 9 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

MARIJUANA (THC150)

	11-nor-∆9-COOH	n per	Site	еA	Sit	eВ	Site	e C
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	75	10	10	0	10	0	10	0
	112.5	10	9	1	9	1	9	1
	187.5	10	2	8	1	9	1	9
	225	10	0	10	0	10	0	10
MA	RIJUANA (THC50)							

11-nor-∆9-COOH

	11-nor-∆ ⁹ -COOH	n per	Sit	эA	Sit	eВ	Site C	
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	25	10	10	0	10	0	10	0
	37.5	10	9	1	8	2	9	1
	62.5	10	1	9	1	9	2	8
	75	10	0	10	0	10	0	10
A A								

MARIJUANA (THC25)

11-nor-∆9-COOH	n per	Site	еA	Sit	eВ	Site C	
conc. (ng/mL)	site	1	+	1	+	-	+
0	10	10	0	10	0	10	0
12.5	10	10	0	10	0	10	0
18.75	10	8	2	8	2	8	2
31.25	10	1	9	1	9	2	8
37.5	10	0	10	0	10	0	10

METHADONE (MTD300)

Methadone	n per	Site	эA	Sit	eВ	Site C	
conc. (ng/mL)	site	1	+	1	+		+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225	10	9	1	9	1	9	1
375	10	1	9	1	9	1	9
450	10	0	10	0	10	0	10

METHADONE (MTD200)

Methadone	n per	Site	еA	Sit	eВ	Site C	
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
100	10	10	0	10	0	10	0
150	10	8	2	8	2	8	2
250	10	1	9	1	9	2	8
300	10	0	10	0	10	0	10
	000						

METHAMPHETAMINE (MET1,000)

Methamphetamine	n per	Site A		Sit	eВ	Site C	
conc. (ng/mL)	site	1	+	1	+	1	+
0	10	10	0	10	0	10	0
500	10	10	0	10	0	10	0
750	10	9	1	9	1	9	1
1,250	10	1	9	2	8	1	9
1,500	10	0	10	0	10	0	10

METHAMPHETAMINE (MET 500)

Methamphetamine	n per	Sit	e A	Sit	eВ	Sit	еC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
250	10	10	0	10	0	10	0
375	10	9	1	9	1	9	1
625	10	1	9	1	9	1	9
750	10	0	10	0	10	0	10

METHAMPHETAMINE (MET300)

Methamphetamine	n per	Sit	e A	Sit	eВ	Sit	e C
conc. (ng/mL)	site	1	+	1	+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225	10	9	1	9	1	9	1
375	10	1	9	1	9	1	9
450	10	0	10	0	10	0	10
) E		

METHYLENEDIOXYMETHAMPHETAMINE (MDMA1, 000) Ecstasy

Methylenedioxymethamphetamine	n per	Sit	e A	Site	өв	Site	eC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
500	10	10	0	10	0	10	0
750	10	9	1	9	1	8	2
1,250	10	1	9	1	9	1	9
1,500	10	0	10	0	10	0	10

Methylenedioxymethamphetamine conc. (ng/mL) n per site + 0 10 10 0 10 10 0 10 250 10 375 10 8 2 9 625

METHYLENEDIOXYMETHAMPHETAMINE (MDMA 500) Ecstasy

Site A Site B

+

Site C

0 10 0

0 10 0

1 9

+

1

625		10	1	9	1	9	1	9
750		10	0	10	0	10	0	10
MORPHINE (MOP 300								
Morphine		n per	Site	эA	Site	eВ	Site	эC
conc. (ng/mL	.)	site	-	+	-	+	-	+
0		10	10	0	10	0	10	0
150		10	10	0	10	0	10	0
225		10	9	1	9	1	9	1
375		10	1	9	1	9	1	9
450		10	0	10	0	10	0	10
MORPHINE (MOP 100)							
Morphine		n per	Site	эA	Site	eВ	Site	эC
conc. (ng/mL	.)	site	-	+	-	+	-	+
0		10	10	0	10	0	10	0
50		10	10	0	10	0	10	0
75		10	9	1	9	1	9	1
125		10	1	9	1	9	1	9
150		10	0	10	0	10	0	10
METHAQUALONE (M	QL 300)							
Methaqualon		n per	Site	эA	Site	вB	Site	эC
conc. (ng/mL		site	-	+	-	+	-	+
0		10	10	0	10	0	10	0
150		10	10	0	10	0	10	0
225		10	9	1	9	1	9	1
375		10	1	9	1	9	1	9
450		10	0	10	0	10	0	10
MORPHINE/OPIATE (OPI 2.000)		-					
Morphine		n per	Site	eΑ	Site	эB	Site	ЭC
conc. (ng/mL	_)	site	-	+	-	+	-	+
0		10	10	0	10	0	10	0
1,000		10	10	0	10	0	10	0
1,500		10	9	1	9	1	9	1
2,500		10	1	9	1	9	1	9
3,000		10	0	10	0	10	0	10
PHENCYCLIDINE (PC	P)	-						
Phencyclidin		n per	Site	e A	Site	еB	Site	e C
conc. (ng/mL		site		+		+	-	+
0	,	10	10	0	10	0	10	0
÷				-		-		-
12.5		10	10	0	10	0	10	0
18.75		10	8	2	9	1	9	1
31.25		10	1	9	1	9	1	9
37.5		10	0	10	0	10	0	10
PROPOXYPHENE (PF	νX)							
Propoxyphen	e	n per	Site	эA	Site	вB	Site	эC
conc. (ng/mL		site	-	+	-	+	-	+
0		10	10	0	10	0	10	0
150		10	10	0	10	0	10	0
225		10	8	2	9	1	9	1
375		10	1	9	1	9	1	9
450		10	0	10	0	10	0	10
TRICYCLIC ANTIDEP	RESSANTS	S (TCA)						
Nortriptyline		n per	Site	эA	Site	еB	Site	эC
conc. (ng/mL	.)	site	-	+	-	+	-	+
0		10	10	0	10	0	10	0
500		10	10	0	10	0	10	0
750		10	9	1	8	2	8	2
1,250		10	1	9	1	9	1	9
1,500		10	0	10	0	10	0	10
Tramadol (TML)								
Tramadol conc. (r	na/mL)	n per	Site	e A	Site	вB	Site	e C
	'9/11∟)	site	-	+	-	+	-	+
0		10	10	0	10	0	10	0
50		10	10	0	10	0	10	0
75		10	9	1	9	1	8	2
125		10	1	9	1	9	2	8
		40	0	40	0	40		40

150

10

10 0 10 0 10 0

KETAMINE (KET1 000)

KE <u>TAMINE (KET1, 000)</u>							
Ketamine conc. (ng/mL)	n per	Site		Site		Site	
	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
500 750	10 10	10 9	0	10 8	0	10 9	0
1,250	10	9 1	9	1	9	2	8
1,500	10	0	10	0	10	0	10
KETAMINE (KET500)	10	Ū	10	Ŭ	10	Ŭ	10
	n per	Site	e A	Site	e B	Site	эC
Ketamine conc. (ng/mL)	site	-	+	-	+	•	+
0	10	10	0	10	0	10	0
250	10	10	0	10	0	10	0
375	10	9	1	9	1	8	2
625 750	10 10	1	9 10	1	9 10	2	8 10
KETAMINE (KET300)	10	0	10	0	10	0	10
	n per	Site	еA	Site	eВ	Site	ЭC
Ketamine conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225	10	9	1	9	1	9	1
375	10	1	9	1	9	1	9
	10	0	10	0	10	0	10
(ETAMINE (KET100)		0.4	o A	01	o P	014	
Ketamine conc. (ng/mL)	n per site	Site	eA +	Site	е В +	Site	эС +
0	10	- 10	+	- 10	+	- 10	+
50	10	10	0	10	0	10	0
75	10	9	1	9	1	9	1
125	10	1	9	1	9	2	8
150	10	0	10	0	10	0	10
Dxycodone (OXY100)							
Oxycodone conc. (ng/mL)	n per	Site		Site		Site	
	site	-	+	-	+	-	+
0	10	10 10	0	10	0	10 10	0
50 75	10 10	9	1	10 9	0	9	1
125	10	1	9	1	9	1	9
150	10	0	10	0	10	0	10
Cotinine (COT 200)							
Cotinine conc. (ng/mL)	n per	Site		Site		Site	
	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
100 150	10 10	10 9	0	10 9	0	10 9	0
250	10	9	9	9	9	2	8
300	10	0	9 10	0	10	0	10
COTININE (COT 100)	10	<u> </u>	. <u> </u>		<u> </u>	L	-
	n per	Site	e A	Site	e B	Site	ЭC
Cotinine conc. (ng/mL)	site	-	+	-	+		+
0	10	10	0	10	0	10	0
					0	10	0
50	10	10	0	10	-	<u>^</u>	
50 75	10	9	1	9	1	9	1
50 75 125	10 10	9 1	1 9	9 1	1 9	1	9
50 75 125 150	10 10 10	9 1 0	1 9 10	9 1 0	1 9 10	1	9 10
50 75 125 150 -ETHYLIDENE-1,5-DIMETHYL-	10 10 10 3,3-DIPH	9 1 0 IENYI	1 9 10 _PYR	9 1 0 ROLIE	1 9 10 DINE (1 0 EDDP	9 10 9 300)
50 75 125 150	10 10 10	9 1 0	1 9 10 _PYR	9 1 0	1 9 10 DINE (1	9 10 9 300)
50 75 125 150 2-ETHYLIDENE-1,5-DIMETHYL-	10 10 10 3,3-DIPH n per	9 1 0 IENYI	1 9 10 PYRI e A	9 1 0 ROLIE	1 9 10 DINE (e B	1 0 EDDP	9 10 9 300) 9 C
50 75 125 150 P-ETHYLIDENE-1,5-DIMETHYL- EDDP conc. (ng/mL) 0 150	10 10 3,3-DIPH n per site 10 10	9 1 9 1ENYI Site - 10 10	1 9 10 • A + 0 0	9 1 0 ROLIE Site - 10 10	1 9 10 0 DINE (e B + 0 0	1 0 EDDF Site - 10 10	9 10 300) e C + 0 0
50 75 125 150 2-ETHYLIDENE-1,5-DIMETHYL- EDDP conc. (ng/mL) 0 150 225	10 10 3,3-DIPH n per site 10 10 10	9 1 9 1 1 9 10 10 9	1 9 10 • A + 0 0 1	9 1 0 ROLIE 5 itt 10 10 9	1 9 10 DINE (e B + 0 0 1	1 0 EDDP Site - 10 10 9	9 10 300) e C + 0 0 1
50 75 125 150 P-ETHYLIDENE-1,5-DIMETHYL- EDDP conc. (ng/mL) 0 150 225 375	10 10 3,3-DIPH n per site 10 10 10 10	9 1 0 IENYI 5 itt 10 10 9 1	1 9 10 • A + 0 0 1 9	9 1 0 ROLIE 5itt 10 10 9 2	1 9 10 DINE (e B + 0 0 1 8	1 0 EDDP 5ite - 10 10 9 1	9 10 9 300) 9 C + 0 0 1 9
50 75 125 150 ETHYLIDENE-1,5-DIMETHYL- EDDP conc. (ng/mL) 0 150 225 375 450	10 10 3,3-DIPH n per site 10 10 10 10	9 1 0 IENYI 5itt 10 10 9 1 0	1 9 10 • PYRI • A + 0 0 1 1 9 10	9 1 0 ROLIE 5itt 10 10 9 2 0	1 9 10 DINE (e B + 0 0 1 8 10	1 0 EDDP Site - 10 10 9 1 0	9 10 9 300) 9 C + 0 0 1 9 10
50 75 125 150 EDDP conc. (ng/mL) 0 150 225 375 450	10 10 3,3-DIPH n per site 10 10 10 10 10 3,3-DIPH	9 1 0 IENYI - 10 10 9 1 0 IENYI	1 9 10 • A + 0 0 1 9 10 - PYRI	9 1 0 ROLIE 5itt 10 10 9 2 0 ROLIE	1 9 10 0 0 8 + 0 0 1 8 10 0 0 1 8	1 0 EDDP 3ite 10 10 9 1 0 EDDP	9 10 300) C + 0 0 1 9 10 100)
50 75 125 150 EDDP conc. (ng/mL) 0 150 225 375 450	10 10 3,3-DIPH n per site 10 10 10 10 3,3-DIPH n per	9 1 0 IENYI 10 10 9 1 0 IENYI Sitt	1 9 10 • A + 0 0 1 9 10 - PYRI • A	9 1 0 ROLIE 5itu - 10 10 9 2 0 0 ROLIE Situ	1 9 10 0 DINE (e B + 0 0 1 8 10 0 DINE (e B	1 0 EDDF Site - 10 10 9 1 0 EDDF Site	9 10 300) ⇒ C + 0 1 9 10 9 10 0 0 100) ⇒ C
50 75 125 150 P-ETHYLIDENE-1,5-DIMETHYL- EDDP conc. (ng/mL) 0 150 225 375 450 P-ETHYLIDENE-1,5-DIMETHYL- EDDP conc. (ng/mL)	10 10 3,3-DIPI n per site 10 10 10 10 10 3,3-DIPI n per site	9 1 0 IENYI - 10 10 9 1 0 IENYI - Site	1 9 10 ▶ PYRI ⊕ A + 0 0 1 9 10 ■ PYRI ⊕ A +	9 1 0 ROLIE 5 10 10 9 2 0 ROLIE Site -	1 9 10 DINE (e B + 0 1 1 8 10 DINE (e B +	1 0 EDDF Site - 10 10 9 1 0 EDDF Site -	9 10 300) ⇒ C + 0 0 1 9 10 9 10 0 • 100) ⇒ C +
50 75 125 150 	10 10 3,3-DIPH n per site 10 10 10 10 10 10 3,3-DIPH n per site 10	9 1 0 IENYI - 10 10 9 1 0 IENYI Site - 10	1 9 10 • A + 0 0 1 9 10 - PYRI • A	9 1 0 ROLIE 5 10 9 2 0 ROLIE Site - 10	1 9 10 DINE (e B + 0 1 1 8 10 DINE (e B + 0	1 0 EDDP Sitte - 10 10 9 1 0 EDDP Sitte - 10	9 10 300) ⇒ C + 0 0 1 9 10 9 10 0 0 0 0 0 0 0 0 0 0 0 0 0
50 75 125 150 2-ETHYLIDENE-1,5-DIMETHYL- EDDP conc. (ng/mL) 0 150 225 375 450 2-ETHYLIDENE-1,5-DIMETHYL- EDDP conc. (ng/mL) 0 50	10 10 3,3-DIPH n per site 10 10 10 10 10 10 10 10 10 10 10 10 10	9 1 0 HENYI 5itt - 10 10 9 1 0 1 HENYI 5itt - 10 10	1 9 10 ▶ PYRI ⊕ A + 0 0 1 9 10 ■ PYRI ⊕ A + 0	9 1 0 ROLIE Sitt - 10 10 9 2 0 ROLIE Sitt - 10 10 10 10 10 10 10 10 10 10	1 9 10 DINE (e B + 0 1 1 8 10 DINE (e B +	1 0 EDDP 3 10 10 9 1 0 EDDP Sitte - 10 10	9 10 300) 3C + 0 0 1 9 10 9 10 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0
50 75 125 150 2-ETHYLIDENE-1,5-DIMETHYL- EDDP conc. (ng/mL) 0 150 225 375 450 2-ETHYLIDENE-1,5-DIMETHYL- EDDP conc. (ng/mL) 0	10 10 3,3-DIPH n per site 10 10 10 10 10 10 3,3-DIPH n per site 10	9 1 0 IENYI - 10 10 9 1 0 IENYI Site - 10	1 9 10 • A • A • 0 0 1 9 10 • A • A • + • 0 • 0 • 0 • 0 • 0 • 0 • 0 • 0 • 0 • 0	9 1 0 ROLIE 5 10 9 2 0 ROLIE Site - 10	1 9 10 DINE (e B + 0 0 1 8 10 DINE (e B + 0 0	1 0 EDDP Sitte - 10 10 9 1 0 EDDP Sitte - 10	9 10 300) ⇒ C + 0 0 1 9 10 9 10 • 0 • 0 • 0 • 0 • • • • • • • • • • • • •

Fentanyl (FYL20)

	FYL conc. (ng/mL)	n per	Sit	еA	Sit	eВ	Site	эC
	FTE CONC. (IIg/IIIE)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	10	10	10	0	10	0	10	0
	15	10	9	1	9	1	9	1
	25	10	1	9	1	9	1	9
	30	10	0	10	0	10	0	10
Fei	ntanyl (FYL10)							
			Cit	o A	Cit.	۰D	Cite	<u> </u>

FYL conc. (ng/mL)	n per	Sit	еA	Site	еB	Site C	
FTE conc. (ng/me)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
5	10	10	0	10	0	10	0
7.5	10	9	1	9	1	9	1
12.5	10	1	9	1	9	1	9
15	10	0	10	0	10	0	10
K2 50							

	K2 conc. (ng/mL)	n per	Site	эA	Site B		Site C	
	KZ CONC. (IIg/IIIE)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	25	10	10	0	10	0	10	0
	37.5	10	8	2	8	2	9	1
	62.5	10	1	9	2	8	2	8
	75	10	0	10	0	10	0	10
K2	30							

K2 <u>30</u>

K2 conc. (ng/mL)	n per	Sit	еA	Sit	εВ	Site	эC
KZ CONC. (IIg/IIIE)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
15	10	10	0	10	0	10	0
22.5	10	8	2	9	1	9	1
37.5	10	1	9	1	9	1	9
45	10	0	10	0	10	0	10

- 01.0

6-MAM

6-MAM conc. (ng/mL)	n per	Site	eА	Sit	eВ	Site	эC
0-WAW COLC. (IIg/IIIE)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
5	10	10	0	10	0	10	0
7.5	10	9	1	9	1	9	1
12.5	10	1	9	1	9	1	9
15	10	0	10	0	10	0	10
 A E00							

MDA 500

MDA conc. (ng/mL)	n per	Site	e A	Site	e B	Site	эC
MDA conc. (ng/mE)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
250	10	10	0	10	0	10	0
375	10	9	1	9	1	9	1
625	10	1	9	1	9	1	9
750	10	0	10	0	10	0	10

ETG500

Ethyl Glucuronide	n per	Sit	eА	Sit	еB	Sit	te C
Concentration (ng/mL)	Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
250	10	10	0	10	0	10	0
375	10	8	2	8	2	9	1
625	10	1	9	2	8	2	8
750	10	0	10	0	10	0	10
ETG1,000							

 01,000							
Ethyl Glucuronide	n per	Sit	e A	Sit	еB	Sit	te C
Concentration (ng/mL)	Site		+	1	+	-	+
0	10	10	0	10	0	10	0
500	10	10	0	10	0	10	0
750	10	8	2	8	2	9	1
1250	10	1	9	2	8	2	8
1500	10	0	10	0	10	0	10
۸n	alvitical S	oncitiv	vitv				

Analytical Sensitivity A drug-free urine pool was spiked with drugs at the listed concentrations. The results are summarized below.

Drug Concentration	AMF	1,00 י כ	AMF	2500	AMP	300	BAR	300	BAR	200	BZC	500	BZC	0300	BZC	0200
Cut-off Range	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	26	4	25	5	27	3	27	3	26	4	27	3	27	3	27	3
Cut-off	15	15	15	15	15	15	16	14	15	15	15	15	15	15	16	14
+25% Cut-off	3	27	3	27	4	26	4	26	3	27	4	26	3	27	3	27
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30

			1						-							
Drug	BZC	0100	В	UP	CC	C300	CO	C100) THC	2150	TH	C50	TH	C25	MTE	0300
Concentration	-	+		+		+		+		+	-	+	_	+	-	+
Cut-off Range	_	т		т	_	т	_	т	_	Ŧ		Ŧ		т	-	Ŧ
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	27	3	26	4	26	-	27	3	27	3	26	4	27	3	27	3
		-	-	_	-		-	-	_			-	-	-	-	
Cut-off	14	16	14	16	13	-	16	14	-	15	14	16	16	14	15	15
+25% Cut-off	3	27	3	27	3	27	4	26	4	26	3	27	4	26	3	27
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
+300 /8 Out-On	0	50	0	50	0	30	U	50	0	50	0	50	0	30	U	50
Drug	МТГ	0200	MET	1,00	МЕТ	500 1	ИЕТЗ	200	MDMA	1,00	MDN	1A50	MO	P300	MOF	200
Concentration		200	0)		000	VIL I C	,00	0		()	1410	000	WICI	200
Cut-off Range	-	+	-	+	-	+	-	+	-	+		+	-	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
		_	30					0					-	-		
-50% Cut-off	30	0		0	30		30		30	0	30	0	30	0	30	0
-25% Cut-off	27	3	26	4	25		27	3	26	4	25	5	26	4	27	3
Cut-off	15	15	14	16	15	15	16	14	15	15	14	16	15	15	16	14
+25% Cut-off	4	26	3	27	4	26	3	27	5	25	4	26	3	27	4	26
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
	-												-	-		
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
Drug	C	DPI	P	СР	F	PX	т	CA	T	٨L	KET		KE	T500	KET	300
Concentration				-				-	_		(
Cut-off Range	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	27	3	26	4	27	3	25	5	27	3	26	4	27	3	26	4
	_			_	_								_			
Cut-off	15	15	15	15	14	16	15	15	15	15	16	14	15	15	15	15
+25% Cut-off	5	25	3	27	4	26	3	27	4	26	4	26	3	27	3	25
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
1000/0 041 011	Ů	00	Ŭ	00	Ŭ	00	v	00	v	00	Ů	00	Ŭ	00	Ů	00
Deve	<u>г</u>		Т		T		T		1		ED	ΠP	E	DDP	1	
Drug	KE.	T100	M	IQL	C	XY	CO	T200	COT	Г100	30			00	FYI	_20
Concentration Cut-off Range	-	Τ.		1.		1.		1.			-			1	-	
÷		+	_	+	_	+	-	+	-	+		+	-	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
		-		_		_		-	_							
-25% Cut-off	27	3	27	3	27	3	27	3	27	3	27	3	27	3	27	3
Cut-off	15	15	15	15	15	15	15	15	14	16	14	16	15	15	15	15
+25% Cut-off	3	27	4	26	4	26	4	26	4	26	4	26	3	27	2	27
	-	-		-	_	_	_	-	-				3	27	3	21
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
	÷						<u> </u>		-				Ŭ	00	v	00
				1/0											==0	
Drug Concentratio	on	FYL	10	K2	50	K	2 30	6-1	MAM 1	0 M	DA 50	00	ETG	500	ETG1	000
Drug Concentratio Cut-off Range	on	FYL -	10 +	K2 -	50 +	- -	2 30	6-1	MAM 1	0 MI	-	+ 00	ETG:	500 +	ETG1 -	+
Cut-off Range		FYL - 30		K2 - 30		- 30	-	-	+	0 MI - 30	-	+	ETG: - 30		ETG1 - 30	
Cut-off Range 0% Cut-off		- 30	+ 0	- 30	+	- 30	+) 3	+ 0 0	-) (+	- 30	+ 0	- 30	+ 0
Cut-off Range 0% Cut-off -50% Cut-off		- 30 30	+ 0 0	- 30 30	+ 0 0	- 30 30	+) 3) 3	+ 0 0 0 0	- 3(3(- 0 (0 (+) :	- 30 30	+ 0 0	- 30 30	+ 0 0
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off		- 30 30 27	+ 0 0 3	- 30 30 26	+ 0 0 4	- 30 30 27	+) 3) 3) 3	+ 0 0 0 0 7 3	- 3(3(2(- 0 (0 (6 4	+) :) : 4 :	- 30 30 26	+ 0 0 4	- 30 30 26	+ 0 0 4
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Cut-off		- 30 30	+ 0 0	- 30 30 26 15	+ 0 0	- 30 30	+ 0) 3) 3 3 2 4 1	+ 0 0 0 0 7 3 5 15	- 3(3(2(5) 1)		+) :) : 4 : 5 :	- 30 30 26 15	+ 0 0 4 15	- 30 30 26 15	+ 0 0 4 15
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off		- 30 30 27	+ 0 0 3	- 30 30 26	+ 0 0 4	- 30 30 27	+) 3) 3 3 2 4 1	+ 0 0 0 0 7 3 5 15	- 3(3(2(5) 1)		+) :) : 4 : 5 :	- 30 30 26	+ 0 0 4	- 30 30 26	+ 0 0 4
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Cut-off +25% Cut-off		- 30 30 27 15 4	+ 0 3 15 26	- 30 30 26 15 3	+ 0 4 15 27	- 30 30 27 16 4	+ () () () () () () () () () () () () ()) 3) 3 3 2 4 1 6 4	+ 0 0 0 0 7 3 5 15 1 26	- 3(3(2(5) 1) 5) 3		+) : 1 5 7	- 30 30 26 15 3	+ 0 4 15 27	- 30 30 26 15 3	+ 0 4 15 27
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Cut-off +25% Cut-off +25% Cut-off +50% Cut-off		- 30 30 27 15 4 0	+ 0 3 15 26 30	- 30 30 26 15 3 0	+ 0 4 15 27 30	- 30 30 27 16 4 0	+ 0 0 3 1 2 3	- 3 3 3 3 4 1 6 4 0 0	+ 0 0 0 0 7 3 5 15 15 15 26 0 30	- 30 30 20 5 15 5 3 6 3 0 0		+) : 1 5 7 0 1 1 1 1 1 1 1 1 1 1 1 1 1	- 30 30 26 15 3 0	+ 0 4 15 27 30	- 30 30 26 15 3 0	+ 0 4 15 27 30
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Cut-off +25% Cut-off		- 30 30 27 15 4	+ 0 3 15 26	- 30 30 26 15 3 0 0	+ 0 4 15 27 30 30	- 30 30 27 16 4 0 0	+ 0 3 1 2 3 3 30		+ 0 0 0 0 7 3 5 15 4 26 0 30 0 30	- 30 30 20 5 15 5 3 6 3 0 0		+) : 1 5 7	- 30 30 26 15 3	+ 0 4 15 27	- 30 30 26 15 3	+ 0 4 15 27
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Cut-off +25% Cut-off +25% Cut-off +50% Cut-off +50% Cut-off		- 30 30 27 15 4 0 0	+ 0 3 15 26 30 30	- 30 30 26 15 3 0 0 0 A	+ 0 4 15 27 30 30 30	- 30 27 16 4 0 0	+ 00 33 14 20 30 30 1 Sp) 3) 3 3 2 4 1 6 4 0 (0) (0) (0	+ 0 0 0 0 7 3 5 15 4 26 0 30 0 30 0 30			+ 0 3 4 3 5 7 0 0 0	- 30 30 26 15 3 0 0	+ 0 4 15 27 30 30	- 30 30 26 15 3 0 0	+ 0 4 15 27 30 30
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Fhe following	table	- 30 30 27 15 4 0 0 0	+ 0 3 15 26 30 30 30	- 30 30 26 15 3 0 0 A I	+ 0 4 15 27 30 30 naly	- 30 30 27 16 4 0 0 tica cent	+ 00 3 1 2 30 30 1 Sp ratio	3 3 3 2 4 1 6 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	+ 0 0 0 0 7 3 5 15 4 26 0 30 0 30 0 30 0 30 0 5 0 5 15 15 15 15 15 15 15 15 15 1	- 30 20 5 15 5 33 6 33 0 0 0 0	- 0 (0 0 (0 6 4 5 1 6 2 1 3 0 3	+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 4 15 27 30 30 30	- 30 30 26 15 3 0 0 0 that	+ 0 4 15 27 30 30
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Fhe following	table	- 30 30 27 15 4 0 0 0	+ 0 3 15 26 30 30 30	- 30 30 26 15 3 0 0 A I	+ 0 4 15 27 30 30 30 naly con	- 30 30 27 16 4 0 0 rtica cent	+ 0 3 1 2 3 30 30 I Sp ratio	- 3 3 3 4 1 6 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	+ 0 0 0 0 7 3 5 15 4 26 0 30 0 30 0 30 0 30 0 5 0 5 15 15 15 15 15 15 15 15 15 1	- 30 20 5 15 5 33 6 33 0 0 0 0	- 0 (0 0 (0 6 4 5 1 6 2 1 3 0 3	+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 4 15 27 30 30 30	- 30 30 26 15 3 0 0 0 that	+ 0 4 15 27 30 30
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off fhe following letected as pos	table	- 30 30 27 15 4 0 0 0	+ 0 3 15 26 30 30 30	- 30 30 26 15 3 0 0 A I	+ 0 4 15 27 30 30 30 naly con	- 30 30 27 16 4 0 0 rtica cent	+ 0 3 1 2 3 30 30 I Sp ratio	- 3 3 3 4 1 6 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	+ 0 0 0 0 7 3 5 15 4 26 0 30 0 30 0 30 0 30 0 5 0 5 15 15 15 15 15 15 15 15 15 1	- 30 20 5 15 5 33 6 33 0 0 0 0	- 0 (0 0 (0 6 4 5 1 6 2 1 3 0 3	+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 4 15 27 30 30 30 mL) minu	- 30 30 26 15 3 0 0 0 that	+ 0 4 15 27 30 30 are
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +25% Cut-off +50% Cut-off +300% Cut-off The following	table	- 30 30 27 15 4 0 0 0	+ 0 3 15 26 30 30 30	- 30 30 26 15 3 0 0 0 A I che e by Con n (ng	+ 0 4 15 27 30 30 30 naly con the cent	- 30 30 27 16 4 0 0 tica cent Mul ratio	+ 0 3 1 2 30 1 5 1 1 1 1 1 1 1 1 1 1 1 1 1	3 3 3 4 6 4 0	+ 0 0 0 0 7 3 5 15 4 26 0 30 0 30 0 0 0 0 0 0 0 0 0 0 0 0 0	- 30 30 20 5 11 5 33 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 4 15 27 30 30 30 mL) minu Cor	- 30 30 26 15 3 0 0 that ites.	+ 0 4 15 27 30 30 are
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off fhe following letected as pos	table	- 30 30 27 15 4 0 0 0	+ 0 3 15 26 30 30 30	- 30 30 26 15 3 0 0 0 A I che e by Con n (ng	+ 0 4 15 27 30 30 30 naly con the cent	- 30 30 27 16 4 0 0 tica cent Mul ratio	+ 0 3 1 2 30 1 5 1 1 1 1 1 1 1 1 1 1 1 1 1	3 3 3 4 6 4 0	+ 0 0 0 0 7 3 5 15 4 26 0 30 0 30 0 0 0 0 0 0 0 0 0 0 0 0 0	- 30 30 20 5 11 5 33 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 4 15 27 30 30 30 mL) minu Cor	- 30 30 26 15 3 0 0 0 that ites.	+ 0 4 15 27 30 30 are
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +50% Cut-off +300% Cut-off +300% Cut-off He following detected as pos Analytes	tabl	- 30 30 27 15 4 0 0 e lis e in	+ 0 3 15 26 30 30 30	- 30 30 26 15 3 0 0 A I the e by Cong	+ 0 4 15 27 30 30 30 naly con the cent	- 30 30 27 16 4 0 0 trica cent Mul ratio	+ 0 0 3 1 3 3 0 1 Sp ratio ti-Di Anal INE		++ 0 0 0 0 7 3 5 15 4 26 0 30 0 30 0 0 0 0 0 0 0 0 0 0 0 0 0	- 30 30 20 5 11 5 33 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 4 15 27 30 30 30 mL) minu Cor n (n	- 30 30 26 15 3 0 0 0 that ites.	+ 0 4 15 27 30 30 are
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off the following detected as pos Analytes D,L-Amphetamin	tabl	- 30 30 27 15 4 0 0 e lis e in	+ 0 3 15 26 30 30 30	- 30 30 26 15 3 0 0 An cond n (ng 300	+ 0 4 15 27 30 30 30 30 cont the centi g/mL	- 30 30 27 16 4 0 0 trica cent Mul ratio	++ C C C C C C C C C C C C C		++ 0 0 0 0 7 3 5 15 4 26 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 0 0	- 30 30 20 5 11 5 33 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 4 15 27 30 30 30 mL) minu Cor n (n	- 30 30 26 15 3 0 0 0 that ites.	+ 0 4 15 27 30 30 are
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off The following Cut-off Analytes D.L-Amphetamine	table sitive	- 30 30 27 15 4 0 0 0 e lis e in	+ 0 3 15 26 30 30 30	- 30 26 15 3 0 0 An che e by Com n (ng 300 25,00	+ 0 4 15 27 30 30 30 30 cont the centi g/mL	- 30 30 27 16 4 0 0 trica cent Mul ratio	++ C C C C C C C C C C C C C		++ 0 0 0 0 7 3 5 15 4 26 0 30 0 4 0 4 0 4 0 4 0 4 0 4 0 4 0			+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 4 15 27 30 30 30 mL) minu Cor n (n 50,0	- 30 30 26 15 3 0 0 0 that ites. bcent g/mL	+ 0 4 15 27 30 30 are
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off +300% Cut-off Fine following detected as pos Analytes D.L-Amphetamine (±) 3,4-Methylene	table sitive	- 30 30 27 15 4 0 0 0 e lis e in	+ 0 3 15 26 30 30 30	- 30 30 26 15 3 0 0 An cond n (ng 300	+ 0 4 15 27 30 30 30 30 cont the centi g/mL	- 30 30 27 16 4 0 0 trica cent Mul ratio	++ C C C C C C C C C C C C C		++ 0 0 0 0 7 3 5 15 4 26 0 30 0 4 0 4 0 4 0 4 0 4 0 4 0 4 0			+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 0 4 15 27 30 30 minu Cor n (n 1,00 50,0 6,00	- 30 30 26 15 3 0 0 0 that ttes. ncent g/mL	+ 0 4 15 27 30 30 are
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off The following Cut-off Analytes D.L-Amphetamine	table sitive	- 30 30 27 15 4 0 0 0 e lis e in	+ 0 3 15 26 30 30 30	- 30 26 15 3 0 0 An he e by Com n (ng 25,00 500	+ 0 4 15 27 30 30 30 30 naly con the centi s/mL		++ CC CC CC CC CC CC CC CC CC CC CC CC C		++ 0 0 0 0 7 3 5 15 4 26 0 30 0 30 0 30 0 30 0 30 0 co Rapio MP 1, ine e henamication			+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 4 15 27 30 30 30 mL) minu Cor n (n 50,0	- 30 30 26 15 3 0 0 0 that ttes. ncent g/mL	+ 0 4 15 27 30 30 are
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off +300% Cut-off Fine following detected as pos Analytes D.L-Amphetamine (±) 3,4-Methylene	table sitive	- 30 30 27 15 4 0 0 0 e lis e in	+ 0 3 15 26 30 30 30	- 30 26 15 3 0 0 An he e by Com n (ng 25,00 500	+ 0 4 15 27 30 30 30 30 naly con the centi s/mL		++ CC CC CC CC CC CC CC CC CC CC CC CC C		++ 0 0 0 0 7 3 5 15 4 26 0 30 0 4 0 4 0 4 0 4 0 4 0 4 0 4 0			+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 0 4 15 27 30 30 minu Cor n (n 1,00 50,0 6,00	- 30 30 26 15 3 0 0 0 that ttes. ncent g/mL	+ 0 4 15 27 30 30 are
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off +300% Cut-off Fine following detected as pos Analytes D.L-Amphetamine (±) 3,4-Methylene	table sitive	- 30 30 27 15 4 0 0 0 e lis e in	+ 0 3 15 26 30 30 30	- 30 26 15 3 0 0 An he e by Com n (ng 25,00 500	+ 0 4 15 27 30 30 30 30 naly con the centi s/mL		++ CC CC CC CC CC CC CC CC CC		+ 0 0 0 0 0 0 0 0 5 15 1 26 0 300			+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 0 4 15 27 30 30 minu Cor n (n 1,00 50,0 6,00	- 30 30 26 15 3 0 0 0 that ites. beg/mL 00 00 00 00 00 00 00 00 00 0	+ 0 4 15 27 30 30 30 are
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off the following detected as pos Analytes D,L-Amphetamine (±) 3,4-Methylene amphetamine	table sitive	- 30 30 27 15 4 0 0 0 e lis e in	+ 0 3 15 26 30 30 30	- 30 26 15 3 0 0 A 1 5 0 Cond n (ng 25,00 500 500 A 150	+ 0 4 15 27 30 30 30 30 con the centu centu con the Centu the Centu con		++ CC CC CC CC CC CC CC CC CC		++ 0 0 0 0 0 0 7 3 3 5 15 4 26 0 3(0) 3 (0) icity of cc Rapid IP 1, ine e henan tamine MP 5 ine			+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 0 4 15 27 30 30 30 TL) Cor n (n 1,000 6,000 1,000 25,0000 25,000 25,000	- 30 30 26 15 3 0 0 0 that ttes. cent to 00 000 000	+ 0 4 15 27 30 30 30 are
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +50% Cut-off +300% Cut-off +300% Cut-off Fhe following D,L-Amphetamine D,L-Amphetamine D,L-Amphetamine	e sult	- 30 30 27 15 4 0 0 0 e lis e in fate	+ 0 3 15 26 30 30 30	- 30 30 26 15 3 0 0 An he e by Con n (ng 25,00 500 AMI 150 12,50	+ 0 4 15 27 30 30 30 30 con the centu centu con the Centu the Centu con		++ C C C C C C C C C C C C C		++ 0 0 0 0 0 0 7 3 3 5 15 4 26 0 3(0) 3(0			+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 0 4 15 27 30 30 mL) Cor n (n 1,00 50,0 500 500	- 30 30 26 15 3 0 0 0 that ttes. cent to 00 000 000	+ 0 4 15 27 30 30 are
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off +300% Cut-off -300% Cut-of	e sult	- 30 30 27 15 4 0 0 0 e lis e in fate	+ 0 3 15 26 30 30 30	- 30 26 15 3 0 0 A 1 5 0 Cond n (ng 25,00 500 500 A 150	+ 0 4 15 27 30 30 30 30 con the centu centu con the Centu Centu Cen		++ C C C C C C C C C C C C C		+ 0 0 0 0 0 0 7 3 5 1 ± 0 30 3 30 1 20 0 300 1 10 1			+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 0 4 15 27 30 30 mL) mL) Cor n (n 500 500 25,(3,00	- 30 30 26 15 3 0 0 0 that ites. 00 000 000 000 000 000	+ 0 4 15 27 30 30 are
Cut-off Range 0% Cut-off -50% Cut-off +25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off he following detected as pos Analytes D.L-Amphetamine (±) 3,4-Methylene amphetamine (±) 3,4-Methylene	e sult	- 30 30 27 15 4 0 0 0 e lis e in fate	+ 0 3 15 26 30 30 30	- 30 26 15 3 0 0 All 500 All 500 All 500 All 500 12,50 250	+ 0 4 15 27 30 30 30 con the centu the centu the centu the con		++ () () () () () () () () () ()		+ 0 0 0 0 0 0 7 3 5 15 4 26 0 30 30 30 icity 0 of c Rapid henan tamine e henan tamine e henan henan tamine			+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 0 4 15 27 30 30 30 TL) Cor n (n 1,000 6,000 1,000 25,0000 25,000 25,000	- 30 30 26 15 3 0 0 0 that ites. 00 000 000 000 000 000	+ 0 4 15 27 30 30 are
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +25% Cut-off +300% Cut-off Fhe following jetected as pos Analytes D,L-Amphetamine D,L-Amphetamine D,L-Amphetamine (±) 3,4-Methylene amphetamine (±) 3,4-Methylene (±) 3,4-Methylene	e sull ediox	- 30 30 27 15 4 0 0 e lis e in fate	+ 0 3 15 26 30 30 30	- 30 30 26 15 3 0 0 An n (ng 25,00 500 AMP 150 12,50 250 AMI	+ 0 4 15 27 30 30 30 con the centu the centu the centu the con		++ C C C C C C C C C C C C C		+ + 0 0 0 0 0 0 0 7 3 5 15 5 15 22 0 30 5 15 15 10 30 0 30 30 30 30 icicity of cs anine anine henan a a b b anine e henan a b b anine MP 1, a b b a b b a b b b a b b a b <td< td=""><td></td><td></td><td>+ 5 7 60 ds (</td><td>- 30 30 26 15 3 0 0 0</td><td>+ 0 0 4 15 27 30 30 30 minut Cor n (n 1,00 50,0 6,00 1,00 50,0 3,00 5,000 5,</td><td>- 30 30 26 15 3 0 0 0 0 0 0 0 0 0 0 0 0 0</td><td>+ 0 4 15 27 30 30 are</td></td<>			+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 0 4 15 27 30 30 30 minut Cor n (n 1,00 50,0 6,00 1,00 50,0 3,00 5,000 5,	- 30 30 26 15 3 0 0 0 0 0 0 0 0 0 0 0 0 0	+ 0 4 15 27 30 30 are
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off -30% Cut-off -	e sull ediox	- 30 30 27 15 4 0 0 e lis e in fate	+ 0 3 15 26 30 30 30	- 30 30 26 15 3 0 0 A 15 6 0 A 15 500 25,00 500 A 112,55 250 A 112,55 250 A 112,55 250 A	+ 0 4 15 27 30 30 30 naly con the centu the Centu HE 00 PHE		++ C C C C C C C C C C C C C		+ 0 0 0 0 0 0 0 0 0 0 7 3 5 15 4 26 0 300 3 0 0 300 3 0 0 300 3 0 0 300 3 0 0 300 0 300 0 300 0 300 0 300 0 300 0 300 0 300 0 300 0 300 0 300 0 300 0 300 0 300 0 300 0 300 0 300 0 300 0			+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 0 4 15 27 30 30 30 mL) minu Cor n (n 1,00 50,0 50,0 1,00 50,0 5,000 5,000	- 30 30 26 15 3 0 0 0 0 0 0 0 0 0 0 0 0 0	+ 0 4 15 27 30 30 are
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off +300% Cut-off +300% Cut-off -300% Cut-off -400% Cut-of	tabla sitive ediox e sult	- 30 30 27 15 4 0 0 0 e list e in fate y fate	+ 0 3 15 26 30 30 30	- 30 30 26 15 3 0 0 An n (ng 25,00 500 AMP 150 12,50 250 AMI	+ 0 4 15 27 30 30 30 naly con the centu the Centu HE 00 PHE		++ CC CC CC CC CC CC CC CC CC CC CC CC C		+ 0 0 0 0 0 0 0 0 0 0 7 3 5 15 4 260 30 300 icity 0 0 300 icity 0 0 300 inine e henann henannine e henannine e e henannine e e e			+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 0 4 15 27 30 30 mL) mIL) mIL) Cor n (n 500, 6,000 1,000 500, 6,000 1,000 500, 0,000 1,000 500, 0,000 1,000 500, 0,000 1,000 5,0000 5,000 5,000 5,000	- 30 30 26 15 3 0 0 0 0 0 0 0 0 0 0 0 0 0	+ 0 4 15 27 30 30 are
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Cut-off +25% Cut-off +50% Cut-off +300% Cut-off +300% Cut-off Che following D,L-Amphetamine D,L-Amphetamine D,L-Amphetamine (±) 3,4-Methylene amphetamine D,L-Amphetamine (±) 3,4-Methylene (±) 3,4-Methylene (±) 3,4-Methylene (±) 3,4-Methylene (±) 3,4-Methylene (±) 3,4-Methylene (±) 3,4-Methylene (±) 3,4-Methylene (±) 3,4-Methylene (±) 3,4-Methylene	tabla sitive ediox e sult	- 30 30 27 15 4 0 0 0 e list e in fate y fate	+ 0 3 15 26 30 30 30	- 30 26 15 3 0 0 An 15 3 0 0 An 15 25,00 500 500 500 500 500 500 500	+ 0 4 15 27 30 30 30 naly con the centu the Centu HE 00 PHE		++ CC CC CC CC CC CC CC CC CC CC CC CC C		+ 0 0 0 0 0 0 0 0 7 3 5 15 12 22 0 33 icity 33 icity 36 0 33 icity 36 icity 37 icity 36 icity 37 icity 36 icity 37 icity 37 icity 38			+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 0 4 15 27 30 30 mL) mIL) Cor n (n 1,00 50,0		+ 0 4 15 27 30 30 are
Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off +300% Cut-off +300% Cut-off -300% Cut-off -400% Cut-of	tabla sitive ediox e sult	- 30 30 27 15 4 0 0 0 e list e in fate y fate	+ 0 3 15 26 30 30 30	- 30 30 26 15 3 0 0 A 15 6 0 A 15 500 25,00 500 A 112,55 250 A 112,55 250 A 112,55 250 A	+ 0 4 15 27 30 30 30 naly con the centu the Centu HE 00 PHE		++ CC CC CC CC CC CC CC CC CC CC CC CC C		+ 0 0 0 0 0 0 0 0 0 0 7 3 5 15 4 260 30 300 icity 0 0 300 icity 0 0 300 inine e henann henannine e henannine e e henannine e e e			+ 5 7 60 ds (- 30 30 26 15 3 0 0 0	+ 0 0 4 15 27 30 30 mL) mIL) mIL) Cor n (n 500, 6,000 1,000 500, 6,000 1,000 500, 0,000 1,000 500, 0,000 1,000 500, 0,000 1,000 5,0000 5,000 5,000 5,000		+ 0 4 15 27 30 30 are

Amobarbital	5,000	JRATES (BAR 300) Alphenol	600
5,5-Diphenylhydantoin	8,000	Aprobarbital	500
Allobarbital	600	Butabarbital	200
Barbital	8,000	Butalbital	8,000
Talbutal	200	Butethal	500
Cyclopentobarbital	30,000	Phenobarbital	300
Pentobarbital	8,000	Secobarbital	300
	BARBITU	JRATES (BAR 200)	
Amobarbital	3,000	Alphenol	400
5,5-Diphenylhydantoin	5,000	Aprobarbital	300
Allobarbital	400	Butabarbital	150
Barbital	5,000	Butalbital	5,000
Talbutal	150	Butethal	300
Cyclopentobarbital	20,000	Phenobarbital	200
Pentobarbital	5,000	Secobarbital	200
		AZEPINES (BZO 500)	4 500
Alprazolam	200 2,500	Bromazepam Chlordiazepoxide	1,500
a-hydroxyalprazolam Clobazam	2,500	Nitrazepam	1,500 300
Clonazepam	800	Norchlordiazepoxide	200
Clorazepate dipotassium	800	Nordiazepam	1,500
Delorazepam	1,500	Oxazepam	500
Desalkylflurazepam	300	Temazepam	300
Flunitrazepam	300	Diazepam	500
(±) Lorazepam	5,000	Estazolam	10,000
RS-Lorazepam glucuronide	300	Triazolam	5,000
Midazolam	10,000		
E	BENZODIA	AZEPINES (BZO 300)	
Alprazolam	100	Bromazepam	900
a-hydroxyalprazolam	1,500	Chlordiazepoxide	900
Clobazam	200	Nitrazepam	200
Clonazepam	500	Norchlordiazepoxide	100
Clorazepate dipotassium	500	Nordiazepam	900
Delorazepam	900	Oxazepam	300
Desalkylflurazepam Flunitrazepam	200 200	Temazepam Diazepam	100 300
(±) Lorazepam	3,000	Estazolam	6,000
RS-Lorazepam glucuronide	200	Triazolam	3.000
Midazolam	6,000	mazolam	5,000
		ZEPINES (BZO 200)	1
Alprazolam	70	Bromazepam	600
a-hydroxyalprazolam	1,000	Chlordiazepoxide	600
Clobazam	120	Nitrazepam	120
Clonazepam	300	Norchlordiazepoxide	70
Clorazepate dipotassium	300	Nordiazepam	600
Delorazepam	600	Oxazepam	200
Desalkylflurazepam	120	Temazepam	70
Flunitrazepam	120	Diazepam	200
(±) Lorazepam	2,000	Estazolam	4,000
RS-Lorazepam glucuronide	120	Triazolam	2,000
Midazolam	4,000		
		AZEPINES (BZO 100)	
Alprazolam	40	Bromazepam	300
a-hydroxyalprazolam	500	Chlordiazepoxide	300
Clobazam	60	Nitrazepam	60
Clonazepam Clorazepate dipotassium	150 150	Norchlordiazepoxide Nordiazepam	40 300
Delorazepate dipotassium	300	Oxazepam	100
Desalkylflurazepam	60	Temazepam	40
	~~		
Flunitrazepam	60		100
	60 1,000	Diazepam Estazolam	100 2,000
Flunitrazepam	1,000 60	Diazepam	
Flunitrazepam (±) Lorazepam	1,000	Diazepam Estazolam	2,000
Flunitrazepam (±) Lorazepam RS-Lorazepam glucuronide	1,000 60 2,000	Diazepam Estazolam	2,000
Flunitrazepam (±) Lorazepam RS-Lorazepam glucuronide	1,000 60 2,000	Diazepam Estazolam Triazolam NORPHINE (BUP) Norbuprenorphine	2,000
Flunitrazepam (±) Lorazepam RS-Lorazepam glucuronide	1,000 60 2,000 BUPRE 10	Diazepam Estazolam Triazolam NORPHINE (BUP) Norbuprenorphine	2,000 1,000
Flunitrazepam (±) Lorazepam RS-Lorazepam glucuronide Midazolam Buprenorphine	1,000 60 2,000 BUPRE 10 de 50	Diazepam Estazolam Triazolam	2,000 1,000 50
Flunitrazepam (±) Lorazepam RS-Lorazepam glucuronide Midazolam Buprenorphine Buprenorphine 3-D-Glucuronic	1,000 60 2,000 BUPRE 10 de 50	Diazepam Estazolam Triazolam NORPHINE (BUP) Norbuprenorphine Norbuprenorphine 3-D-Glucuronide AINE (COC 300)	2,000 1,000 50 100
Flunitrazepam (±) Lorazepam RS-Lorazepam glucuronide Midazolam Buprenorphine Buprenorphine 3-D-Glucuronio Benzoylecgonine	1,000 60 2,000 BUPRE 10 de 50 COC/	Diazepam Estazolam Triazolam NORPHINE (BUP) Norbuprenorphine Norbuprenorphine 3-D-Glucuronide	2,000 1,000 50
Flunitrazepam (±) Lorazepam RS-Lorazepam glucuronide Midazolam Buprenorphine Buprenorphine 3-D-Glucuronio Benzoylecgonine	1,000 60 2,000 BUPRE 10 10 50 COC/ 300 200	Diazepam Estazolam Triazolam NORPHINE (BUP) Norbuprenorphine Norbuprenorphine 3-D-Glucuronide AINE (COC 300) Cocaethylene Ecgonine	2,000 1,000 50 100 20,000
Flunitrazepam (±) Lorazepam RS-Lorazepam glucuronide Midazolam Buprenorphine Buprenorphine 3-D-Glucuronic Benzoylecgonine Cocaine HCI	1,000 60 2,000 BUPRE 10 10 50 COC/ 300 200	Diazepam Estazolam Triazolam NORPHINE (BUP) Norbuprenorphine Norbuprenorphine 3-D-Glucuronide AINE (COC 300) Cocaethylene	2,000 1,000 50 100 20,000
Flunitrazepam (±) Lorazepam RS-Lorazepam glucuronide Midazolam Buprenorphine Buprenorphine 3-D-Glucuronic Benzoylecgonine Cocaine HCI	1,000 60 2,000 BUPRE 10 10 50 COC/ 300 200 COC/	Diazepam Estazolam Triazolam NORPHINE (BUP) Norbuprenorphine Norbuprenorphine 3-D-Glucuronide AINE (COC 300) Cocaethylene Ecgonine AINE (COC 100)	2,000 1,000 50 100 20,000 30,000
Flunitrazepam (±) Lorazepam RS-Lorazepam glucuronide Midazolam Buprenorphine Buprenorphine 3-D-Glucuronic Benzoylecgonine Cocaine HCI Benzoylecgonine	1,000 60 2,000 BUPRE 10 10 50 COC/ 300 200 COC/ 100 80	Diazepam Estazolam Triazolam NORPHINE (BUP) Norbuprenorphine Norbuprenorphine 3-D-Glucuronide AINE (COC 300) Cocaethylene Ecgonine AINE (COC 100) Cocaethylene Ecgonine	2,000 1,000 50 100 20,000 30,000 7,000
Flunitrazepam (±) Lorazepam glucuronide Midazolam Buprenorphine Buprenorphine 3-D-Glucuronic Benzoylecgonine Cocaine HCl Benzoylecgonine Cocaine HCl	1,000 60 2,000 BUPRE 10 10 50 COC/ 300 200 COC/ 100 80 MARIJ	Diazepam Estazolam Triazolam Norbuprenorphine Norbuprenorphine 3-D-Glucuronide AINE (COC 300) Cocaethylene Ecgonine AINE (COC 100) Cocaethylene	2,000 1,000 50 100 20,000 30,000 7,000
Flunitrazepam (±) Lorazepam Midazolam Buprenorphine Buprenorphine 3-D-Glucuronic Benzoylecgonine Cocaine HCI Benzoylecgonine Cocaine HCI Cocaine HCI Cannabinol	1,000 60 2,000 BUPRE 10 10 50 COC/ 300 200 COC/ 100 80	Diazepam Estazolam Triazolam NORPHINE (BUP) Norbuprenorphine Norbuprenorphine 3-D-Glucuronide AINE (COC 300) Cocaethylene Ecgonine AINE (COC 100) Cocaethylene Ecgonine UANA (THC150)	2,000 1,000 50 100 20,000 30,000 7,000 10,000
Flunitrazepam (±) Lorazepam Midazolam Buprenorphine Buprenorphine 3-D-Glucuronic Benzoylecgonine Cocaine HCI Benzoylecgonine Cocaine HCI Cocaine HCI Cannabinol	1,000 80 2,000 BUPRE 10 10 50 COC/ 300 200 COC/ 100 80 MARIJ 100,000	Diazepam Estazolam Triazolam NORPHINE (BUP) Norbuprenorphine Norbuprenorphine 3-D-Glucuronide AINE (COC 300) Cocaethylene Ecgonine AINE (COC 100) Cocaethylene Ecgonine UANA (THC150) △8-THC	2,000 1,000 50 100 20,000 30,000 7,000 10,000 50,000
Flunitrazepam (±) Lorazepam RS-Lorazepam glucuronide Midazolam Buprenorphine 3-D-Glucuronic Benzoylecgonine Cocaine HCI Benzoylecgonine Cocaine HCI Cannabinol 11-nor-∆8-THC-9 COOH	1,000 80 2,000 BUPRE 10 300 200 COC/ 300 200 COC/ 100 80 MARIJ 100,000 150	Diazepam Estazolam Triazolam NORPHINE (BUP) Norbuprenorphine Norbuprenorphine 3-D-Glucuronide AINE (COC 300) Cocaethylene Ecgonine AINE (COC 100) Cocaethylene Ecgonine IUANA (THC150) △8-THC △9-THC	2,000 1,000 50 100 20,000 30,000 7,000 10,000 50,000
Flunitrazepam (±) Lorazepam glucuronide Midazolam Buprenorphine Buprenorphine 3-D-Glucuronid Benzoylecgonine Cocaine HCI Benzoylecgonine Cocaine HCI Cannabinol 11-nor-△8-THC-9 COOH 11-nor-△9-THC-9 COOH	1,000 80 2,000 BUPRE 10 300 200 COC/ 300 200 COC/ 100 80 MARIJ 100,000 150	Diazepam Estazolam Triazolam NORPHINE (BUP) Norbuprenorphine Norbuprenorphine 3-D-Glucuronide AINE (COC 300) Cocaethylene Ecgonine AINE (COC 100) Cocaethylene Ecgonine UANA (THC150) A8-THC A9-THC JUANA (THC50)	2,000 1,000 100 20,000 30,000 7,000 10,000 50,000 50,000
Flunitrazepam (±) Lorazepam RS-Lorazepam glucuronide Midazolam Buprenorphine Buprenorphine 3-D-Glucuronid Benzoylecgonine Cocaine HCI Benzoylecgonine Cocaine HCI Cannabinol 11-nor-△8-THC-9 COOH 11-nor-△9-THC-9 COOH Cannabinol	1,000 80 2,000 BUPRE 10 50 COC/ 300 200 COC/ 100 80 MARIJ 100,000 150 MARIJ	Diazepam Estazolam Triazolam NORPHINE (BUP) Norbuprenorphine Norbuprenorphine 3-D-Glucuronide AINE (COC 300) Cocaethylene Ecgonine AINE (COC 100) Cocaethylene Ecgonine UUANA (THC150) △B-THC → JUANA (THC50) △B-THC	2,000 1,000 1,000 100 20,000 30,000 7,000 10,000 50,000 50,000 17,000
Flunitrazepam (±) Lorazepam glucuronide Midazolam Buprenorphine Buprenorphine 3-D-Glucuronid Benzoylecgonine Cocaine HCI Benzoylecgonine Cocaine HCI Cannabinol 11-nor-△8-THC-9 COOH 11-nor-△9-THC-9 COOH	1,000 80 2,000 BUPRE 10 300 200 COC/ 100 80 MARIJ 100,000 100 100 100 MARIJ 35,000	Diazepam Estazolam Triazolam NORPHINE (BUP) Norbuprenorphine Norbuprenorphine 3-D-Glucuronide AINE (COC 300) Cocaethylene Ecgonine AINE (COC 100) Cocaethylene Ecgonine UANA (THC150) A8-THC A9-THC JUANA (THC50)	2,000 1,000 100 20,000 30,000 7,000 10,000 50,000 50,000
Flunitrazepam (±) Lorazepam RS-Lorazepam glucuronide Midazolam Buprenorphine 3-D-Glucuronide Benzoylecgonine Cocaine HCI Benzoylecgonine Cocaine HCI Cocaine HCI Cannabinol 11-nor-∆9-THC-9 COOH Cannabinol 11-nor-∆8-THC-9 COOH	1,000 80 2,000 BUPRE 10 50 COC/ 300 200 COC/ 100 80 MARIJ 100,000 150 MARI 35,000 30 50	Diazepam Estazolam Triazolam NORPHINE (BUP) Norbuprenorphine Norbuprenorphine 3-D-Glucuronide AINE (COC 300) Cocaethylene Ecgonine AINE (COC 100) Cocaethylene Ecgonine UANA (THC150) \triangle 8-THC \triangle 9-THC \triangle 9-THC \triangle 9-THC	2,000 1,000 1,000 100 20,000 30,000 7,000 10,000 50,000 50,000 17,000
Flunitrazepam (±) Lorazepam glucuronide Midazolam Buprenorphine Buprenorphine 3-D-Glucuronide Benzoylecgonine Cocaine HCI Benzoylecgonine Cocaine HCI Cannabinol 11-nor-△8-THC-9 COOH Cannabinol 11-nor-△8-THC-9 COOH	1,000 80 2,000 BUPRE 10 50 COC/ 300 200 COC/ 100 80 MARIJ 100,000 150 MARI 35,000 30 50	Diazepam Estazolam Triazolam NORPHINE (BUP) Norbuprenorphine Norbuprenorphine 3-D-Glucuronide AINE (COC 300) Cocaethylene Ecgonine AINE (COC 100) Cocaethylene Ecgonine UUANA (THC150) △B-THC → JUANA (THC50) △B-THC	2,000 1,000 1,000 100 20,000 30,000 7,000 10,000 50,000 50,000 17,000

11-nor-△8-THC-9 COOH	15	△9-THC	8,500
11-nor-△9-THC-9 COOH	25 METH/	ADONE (MTD300)	1
Methadone	300	Doxylamine	100,000
		ADONE (MTD200)	100,000
/lethadone	200	Doxylamine	65,000
	THAMPH	IETAMINE (MET1, 000)	
-Hydroxymethamphetamine	25,000	(±)-3,4-Methylenedioxy-	12,500
D-Methamphetamine	1,000 20,000	methamphetamine Mephentermine	50,000
-Methamphetamine		HETAMINE (MET500)	50,000
-Hydroxymethamphetamine	12,500	(±)-3,4-Methylenedioxy-	6,250
D-Methamphetamine	500	methamphetamine	0,200
-Methamphetamine	10,000	Mephentermine	25,000
N	IETHAMP	HETAMINE (MET300)	
-Hydroxymethamphetamine	7,500	(±)-3,4-Methylenedioxy-	3,750
D-Methamphetamine Methamphetamine	300 6,000	methamphetamine Mephentermine	15.000
		MPHETAMINE (MDMA1, 000) E	
			.031039
(±) 3,4-Methylenedioxy methamphetamine HCl	1,000	3,4-Methylenedioxyethyl-amphetami ne	600
±) 3,4-Methylenedioxyamphetam 9 HCl	in6,000		
	XYMETH	AMPHETAMINE (MDMA500) Ec	stasy
±) 3,4-Methylenedioxy	1	3,4-Methylenedioxyethyl-amphetami	· ·
nethamphetamine HCI	500	ne	300
(±) 3,4-Methylenedioxyamphetam	in3,000		
e HCI	MORE	PHINE (MOP 300)	1
Codeine	200	Norcodeine	6,000
_evorphanol	1,500	Normorphone	50,000
Morphine-3-β-D-Glucuronide	800	Oxycodone	30,000
Ethylmorphine	6,000	Oxymorphone	50,000
Hydrocodone Hydromorphone	50,000 3,000	Procaine Thebaine	15,000 6,000
5-Monoacethylmorphine	300	Morphine	300
		PHINE (MOP 100)	•
Codeine	80	Norcodeine	2,000
_evorphanol	500	Normorphone	20,000
Morphine-3-β-D-Glucuronide	300	Oxycodone	10,000
Ethylmorphine Hydrocodone	2,000 20,000	Oxymorphone Procaine	20,000 5,000
Hydromorphone	1,000	Thebaine	2,000
6-Monoacethylmorphine	200	Morphine	100
	Methaq	ualone (MQL 300)	
Vlethaqualone	300		
Padaina		NE/OPIATE (OPI 2,000)	0.000
Codeine Ethylmorphine	2,000 3,000	Morphine Norcodeine	2,000 25,000
Hydrocodone	50,000	Normorphone	50,000
Hydromorphone	15,000	Oxycodone	25,000
Levorphanol	25,000	Oxymorphone	25,000
6-Monoacetylmorphine Morphine 3-β-D-glucuronide	3,000 2,000	Procaine	50,000 25,000
worphille s-p-D-gluculonide		Thebaine CYCLIDINE (PCP)	20,000
Phencyclidine	25	4-Hydroxyphencyclidine	12,500
		DXYPHENE (PPX)	. 2,000
D-Propoxyphene	300	D-Norpropoxyphene	300
		ITIDEPRESSANTS (TCA)	•
Nortriptyline	1,000	Imipramine	400
Nordoxepine	500	Clomipramine	50,000
Trimipramine	3,000	Doxepine Maprotiline	2,000
Amitriptyline Promazine	3,000	Promethazine	2,000 50,000
Desipramine	200	Perphenazine	50,000
Cyclobenzaprine	2,000		
		amadol (TML)	
n-Desmethyl-cis-tramadol	200	o-Desmethyl-cis-tramadol	10,000
Cis-tramadol Procyclidine	100	Phencyclidine d,I-O-Desmethyl venlafaxine	100,000 50,000
Tooyollullio		MINE (KET1, 000)	00,000
Ketamine	1,000	Benzphetamine	25,000
Dextromethorphan	2,000	(+) Chlorpheniramine	25,000
Methoxyphenamine	25,000	Clonidine	100,000
I-Norpropoxyphene	25,000	EDDP	50,000
Promazine	25,000 25,000	4-Hydroxyphencyclidine Levorphanol	50,000 50,000
Promethazine Pentazocine	25,000	MDE	50,000

Tetrahydrozoline	500	d-Methamphetamine	50,000
Mephentermine (1R, 2S) - (-)-Ephedrine	25,000 100,000	I-Methamphetamine 3,4-Methylendioxymethamphetamine	50,000
TR, 23) - (-)-Epheunne	100,000	(MDMA)	100,000
Disopyramide	25,000	Thioridazine	50,000
		MINE (KET500)	
Ketamine	500	Benzphetamine	12,500
Dextromethorphan Methoxyphenamine	1,000 12,500	(+) Chlorpheniramine Clonidine	12,500 50,000
d-Norpropoxyphene	12,500	EDDP	25,000
Promazine	12,500	4-Hydroxyphencyclidine	25,000
Promethazine	12,500	Levorphanol	25,000
Pentazocine	12,500	MDE	25,000
Phencyclidine Tetrahydrozoline	12,500	Meperidine	12,500
Tetrahydrozoline	250	d-Methamphetamine	25,000
Mephentermine	12,500	I-Methamphetamine	25,000
(1R, 2S) - (-)-Ephedrine	50,000	3,4-Methylendioxymethamphetamine (MDMA)	50,000
Disopyramide	12.500	Thioridazine	25,000
	KETA	MINE (KET300)	
Ketamine	300	Benzphetamine	6,250
Dextromethorphan	600	(+) Chlorpheniramine	6,250
Vethoxyphenamine	6,250	Clonidine	30,000
-Norpropoxyphene Promazine	6,250	EDDP	15,000
romazine	6,250	4-Hydroxyphencyclidine	15,000
Promethazine	6,250	Levorphanol	15,000
Pentazocine	6,250	MDE	15,000
Phencyclidine Tetrahydrozoline	6,250	Meperidine d-Methamphetamine	6,250 15.000
Mephentermine	150 6,250	d-Methamphetamine	15,000 15,000
1R, 2S) - (-)-Ephedrine	30,000	3,4-Methylendioxymethamphetamine	
	-	(MDMA)	
Disopyramide	6,250	Thioridazine	15,000
	KETA	MINE (KET100)	
Ketamine	100	Benzphetamine	2,000
Dextromethorphan	200	(+) Chlorpheniramine	2,000
Methoxyphenamine	2,000	Clonidine	10,000
d-Norpropoxyphene Promazine	2,000	EDDP	5,000
Promazine	2,000	4-Hydroxyphencyclidine	5,000
Promethazine Pentazocine	2,000	Levorphanol MDE	5,000 5,000
Phencyclidine	2,000	Meperidine	2,000
Tetrahydrozoline	50	d-Methamphetamine	5,000
Vephentermine	2,000	I-Methamphetamine	5,000
1R, 2S) - (-)-Ephedrine	10,000	Thioridazine	5,000
Disopyramide	2,000	3,4-Methylendioxymethamphetamine	
	-	(MDMA)	
	100 UXYCO	done (OXY100)	50.000
Oxycodone Oxymorphone	300	Hydromorphone Naloxone	50,000 25,000
Levorphanol	50,000	Naltrexone	25,000
Hydrocodone	25,000	Namexone	20,000
		ine (COT 200)	
-)-Cotinine	200	(-)-Nicotine	5,000
	Cotin	ine (COT 100)	
-)-Cotinine	100	(-)-Nicotine	2,500
2-Ethylidene-1,5	-dimethyl-		P300)
2-Ethylidene-1,5 2-Ethylidene-1,5-dimethyl-3,3-	diphenylpyrro	3,3-diphenylpyrrolidine (EDDF	300) 300
2-Ethylidene-1,5-dimethyl-3,3-	diphenylpyrro	3,3-diphenylpyrrolidine (EDDF	300
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5	diphenylpyrro dimethyl-	3,3-diphenylpyrrolidine (EDDF idine (EDDP) 3,3-diphenylpyrrolidine (EDDF	300
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5 2-Ethylidene-1,5-dimethyl-3,3-	diphenylpyrrol -dimethyl- diphenylpyrrol Fent	3,3-diphenylpyrrolidine (EDDF lidine (EDDP) 3,3-diphenylpyrrolidine (EDDF lidine (EDDP) anyl (FYL20)	300 2 100) 100
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5 2-Ethylidene-1,5-dimethyl-3,3-	diphenylpyrro -dimethyl- diphenylpyrro Fent 600,000	3,3-diphenylpyrrolidine (EDDF) idine (EDDP) 3,3-diphenylpyrrolidine (EDDF) idine (EDDP) anyl (FYL20) Buspirone	300 2100) 100 15,000
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5 2-Ethylidene-1,5-dimethyl-3,3- Alfentanyl Fenfluramine	diphenylpyrro diphenylpyrro Fent 600,000 50,000	3,3-diphenylpyrrolidine (EDDF) 3,3-diphenylpyrrolidine (EDDF) idine (EDDP) tanyl (FYL20) Buspirone Fentanyl	300 2100) 100 15,000 100
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5 2-Ethylidene-1,5-dimethyl-3,3- Alfentanyl Fenfluramine	diphenylpyrroi i-dimethyl- diphenylpyrroi Fent 600,000 50,000 20	3,3-diphenylpyrrolidine (EDDF idine (EDDP) 3,3-diphenylpyrrolidine (EDDF idine (EDDP) anyl (FYL20) Buspirone Fentanyl Sufentanyl	300 2100) 100 15,000
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5 2-Ethylidene-1,5-dimethyl-3,3- Alfentanyl Fenfluramine Norfentanyl Norfentanyl	diphenylpyrroi i-dimethyl- diphenylpyrroi Fent 600,000 50,000 20	3,3-diphenylpyrrolidine (EDDF) 3,3-diphenylpyrrolidine (EDDF) idine (EDDP) tanyl (FYL20) Buspirone Fentanyl	300 2100) 100 15,000 100
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5 2-Ethylidene-1,5-dimethyl-3,3- Alfentanyl Fenfluramine Norfentanyl Alfentanyl	diphenylpyrro -dimethyl- diphenylpyrro Fent 600,000 50,000 20 Fent 300,000	3,3-diphenylpyrrolidine (EDDF) idine (EDDP) 3,3-diphenylpyrrolidine (EDDF) idine (EDDP) anyl (FYL20) Buspirone Fentanyl Sufentanyl anyl (FYL10) Buspirone	300 2100) 100 15,000 100 50,000 8,000
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5 2-Ethylidene-1,5-dimethyl-3,3- Alfentanyl Fenfluramine Norfentanyl Genfluramine	diphenylpyrro -dimethyl- diphenylpyrro Fent 600,000 50,000 20 Fent 300,000 25,000	3,3-diphenylpyrrolidine (EDDF idine (EDDP) 3,3-diphenylpyrrolidine (EDDF idine (EDDP) anyl (FYL20) Buspirone Fentanyl Sufentanyl Buspirone Fentanyl Buspirone Fentanyl	300 2100) 100 15,000 100 50,000 8,000 50
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5 2-Ethylidene-1,5-dimethyl-3,3- Alfentanyl Fenfluramine Norfentanyl Genfluramine	diphenylpyrro -dimethyl- diphenylpyrro Fent 600,000 50,000 20 Fent 300,000 25,000 10	3,3-diphenylpyrrolidine (EDDF) 3,3-diphenylpyrrolidine (EDDF) idine (EDDP) anyl (FYL20) Buspirone Fentanyl Sufentanyl anyl (FYL10) Buspirone Fentanyl Sufentanyl Sufentanyl Sufentanyl Sufentanyl	300 2100) 100 15,000 100 50,000 8,000
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5- 2-Ethylidene-1,5-dimethyl-3,3- Alfentanyl Fenfluramine Norfentanyl Alfentanyl Fenfluramine Norfentanyl Norfentanyl	diphenylpyrrol -dimethyl- diphenylpyrrol Fent 600,000 20 Fent 300,000 25,000 10 Synthetic	3,3-diphenylpyrrolidine (EDDF) 3,3-diphenylpyrrolidine (EDDF) idine (EDDP) anyl (FYL20) Buspirone Fentanyl Sufentanyl anyl (FYL10) Buspirone Fentanyl Sufentanyl Marijuana (K2-50)	B00 2100) 1100 1100 15,000 100 50,000 8,000 50 25,000
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5- 2-Ethylidene-1,5-dimethyl-3,3- Varientanyl -enfluramine Vorfentanyl -enfluramine -enfluramine Vorfentanyl Vorfentanyl	diphenylpyrro -dimethyl- diphenylpyrro Fent 600,000 50,000 20 Fent 300,000 25,000 10 Synthetic 60	3,3-diphenylpyrrolidine (EDDF) idine (EDDP) 3,3-diphenylpyrrolidine (EDDF) idine (EDDP) anyl (FYL20) Buspirone Fentanyl Sufentanyl Buspirone Fentanyl Fentanyl Sufentanyl Sufentanyl Sufentanyl Marijuana (K2-50) JWH-073 4-butanoic acid	300 2100) 100 15,000 100 50,000 8,000 8,000 50 50 50
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5- 2-Ethylidene-1,5-dimethyl-3,3- Varientanyl -enfluramine Vorfentanyl -enfluramine -enfluramine Vorfentanyl Vorfentanyl	diphenylpyrro -dimethyl- diphenylpyrro Fent 600,000 20 50,000 25,000 10 Synthetic 50 400	3,3-diphenylpyrrolidine (EDDF) 3,3-diphenylpyrrolidine (EDDF) idine (EDDP) anyl (FYL20) Buspirone Fentanyl Sufentanyl anyl (FYL10) Buspirone Fentanyl Sufentanyl Marijuana (K2-50)	B00 2100) 1100 1100 15,000 100 50,000 8,000 50 25,000
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5- 2-Ethylidene-1,5-dimethyl-3,3- Varientanyl -enfluramine Vorfentanyl -enfluramine -enfluramine Vorfentanyl Vorfentanyl	diphenylpyrro -dimethyl- diphenylpyrro Fent 600,000 20 Fent 300,000 25,000 10 Synthetic 50 400 500	3,3-diphenylpyrrolidine (EDDF) idine (EDDP) 3,3-diphenylpyrrolidine (EDDF) idine (EDDP) Buspirone Fentanyl Sufentanyl surj (FYL10) Buspirone Fentanyl Sufentanyl Sufentanyl Marijuana (K2-50) JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl	300 100 100 100 50,000 8,000 8,000 50 50 50
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5- 2-Ethylidene-1,5- Alfentanyl Fenfluramine Norfentanyl Alfentanyl Alfentanyl Wh-018 5-Pentanoic acid JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty	diphenylpyrro -dimethyl- diphenylpyrro Fent 800,000 50,000 20 Fent 300,000 25,000 10 Synthetic 50 400 500 Synthetic	3,3-diphenylpyrrolidine (EDDF) idine (EDDP) 3,3-diphenylpyrrolidine (EDDF) idine (EDDP) anyl (FYL20) Buspirone Fentanyl Sufentanyl Buspirone Fentanyl Sufentanyl Marijuana (K2-50) JWH-073 4-butanoic acid JWH-073 4-butanoic acid	300 >100) 100 15,000 100 50,000 8,000 50 25,000 50 500
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5- 2-Ethylidene-1,5- Alfentanyl Fenfluramine Norfentanyl Alfentanyl Alfentanyl Wh-018 5-Pentanoic acid JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty	diphenylpyrro -dimethyl- diphenylpyrro Fent 600,000 20 Fent 300,000 25,000 10 Synthetic 50 400 500	3,3-diphenylpyrrolidine (EDDF) 3,3-diphenylpyrrolidine (EDDF) 3,3-diphenylpyrrolidine (EDDF) idine (EDDP) anyl (FYL20) Buspirone Fentanyl Sufentanyl Sufentanyl Sufentanyl Sufentanyl Marijuana (K2-30) JWH-073 4-butanoic acid JWH-073 4-butanoic acid	300 100 100 100 50,000 8,000 8,000 50 50 50
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5- 2-Ethylidene-1,5- Alfentanyl Fenfluramine Norfentanyl Alfentanyl Alfentanyl Wh-018 5-Pentanoic acid JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty	diphenylpyrro i-dimethyl- diphenylpyrro Fent 600,000 50,000 20 Fent 300,000 25,000 10 Synthetic 50 400 500 Synthetic 30	3,3-diphenylpyrrolidine (EDDF) idine (EDDP) 3,3-diphenylpyrrolidine (EDDF) idine (EDDP) anyl (FYL20) Buspirone Fentanyl Sufentanyl Buspirone Fentanyl Sufentanyl Marijuana (K2-50) JWH-073 4-butanoic acid JWH-073 4-butanoic acid	300 >100) 100 15,000 100 50,000 8,000 50 25,000 50 50 300
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5- 2-Ethylidene-1,5-dimethyl-3,3- Alfentanyl Fenfluramine Vorfentanyl Wife	diphenylpyrroi -dimethyl- diphenylpyrroi Fent 600,000 50,000 20 Fent 300,000 25,000 10 Synthetic 50 50 Synthetic 300 300 300 250	3,3-diphenylpyrrolidine (EDDF) idine (EDDP) 3,3-diphenylpyrrolidine (EDDF) idine (EDDP) anyl (FYL20) Buspirone Fentanyl Sufentanyl Buspirone Fentanyl Sufentanyl Marijuana (K2-50) JWH-073 4-butanoic acid JWH-073 4-butanoic acid JWH-073 4-butanoic acid JWH-073 4-butanoic acid JWH-073 4-butanoic acid JWH-073 4-butanoic acid JWH-073 4-butanoic acid	300 >100) 100 15,000 100 50,000 8,000 50 25,000 50 50 300
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5- 2-Ethylidene-1,5- Alfentanyl Fenfluramine Norfentanyl Alfentanyl Fenfluramine Norfentanyl JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-018 4-Hydroxybuty JWH-018 4-Hydroxypentyl JWH-018 4-Hydroxypentyl JWH-018 4-Hydroxypentyl JWH-018 4-Hydroxypentyl JWH-018 4-Hydroxypentyl JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty 6-	diphenylpyrroi -dimethyl- diphenylpyrroi Fent 600,000 50,000 20 Fent 300,000 25,000 10 Synthetic 50 50 Synthetic 300 300 300 250	3,3-diphenylpyrrolidine (EDDF) 3,3-diphenylpyrrolidine (EDDF) 3,3-diphenylpyrrolidine (EDDF) idine (EDDP) anyl (FYL20) Buspirone Fentanyl Sufentanyl Sufentanyl Sufentanyl Marijuana (K2-50) JWH-073 4-butanoic acid JWH-073 4-butanoic acid JWH-075 4-butanoic ac	300 >100) 100 15,000 100 50,000 8,000 50 25,000 50 50 300
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5- 2-Ethylidene-1,5- Alfentanyl Fenfluramine Norfentanyl Alfentanyl MH-018 5-Pentanoic acid JWH-018 5-Pentanoic acid JWH-018 5-Pentanoic acid JWH-018 5-Pentanoic acid JWH-018 5-Pentanoic acid JWH-018 5-Pentanoic acid JWH-018 4-Hydroxybuty JWH-018 4-Hydroxybuty JWH-018 4-Hydroxybuty JWH-018 4-Hydroxybuty MH-018 4-Hydroxybuty G- Codeine	diphenylpyrrol -dimethyl- diphenylpyrrol Bionov Fent 600,000 20 Fent 300,000 25,000 10 Synthetic 50 50 400 500 Synthetic 30 2550 300 mono-acel	3,3-diphenylpyrrolidine (EDDF) idine (EDDP) 3,3-diphenylpyrrolidine (EDDF) idine (EDDP) anyl (FYL20) Buspirone Fentanyl Sufentanyl Buspirone Fentanyl Sufentanyl Marijuana (K2-50) JWH-073 4-butanoic acid JWH-073 4-butanoic acid JWH-073 4-butanoic acid JWH-073 4-butanoic acid JWH-073 4-butanoic acid JWH-073 4-butanoic acid JWH-073 4-butanoic acid	300 100) 100 15,000 100 50,000 8,000 50 50 50 50 300 300
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5- 2-Ethylidene-1,5-dimethyl-3,3- Alfentanyl Fenfluramine Norfentanyl Alfentanyl Alfentanyl Fenfluramine Norfentanyl JWH-018 5-Pentanoic acid JWH-018 5-Pentanoic acid JWH-018 5-Pentanoic acid JWH-018 5-Pentanoic acid JWH-018 5-Pentanoic acid JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-018 4-Hydroxypentyl JWH-03 4-Hydroxypentyl JWH-03 4-Hydroxypentyl JWH-073 4-Hydroxypentyl JWH-073 4-Hydroxypentyl JWH-073 4-Hydroxypentyl JWH-073 4-Hydroxypentyl JWH-073 4-Hydroxypentyl JWH-073 4-Hydroxypentyl JWH-075 4-Hydroxype	diphenylpyrro i-dimethyl- diphenylpyrro Fent 600,000 50,000 20 Fent 300,000 25,000 10 Synthetic 50 500 Synthetic 30 500 500 500 500 500 500 500	3,3-diphenylpyrrolidine (EDDF) 3,3-diphenylpyrrolidine (EDDF) 3,3-diphenylpyrrolidine (EDDF) anyl (FYL20) Buspirone Fentanyl Sufentanyl Sufentanyl Buspirone Fentanyl Sufentanyl Marijuana (K2-50) JWH-073 4-butanoic acid JWH-073 4-butanoic acid JWH-078 5-Hydroxypentyl bo-morphine (6-MAM) Morphine Norcodeine	300 2100) 100 15,000 100 50,000 8,000 50 25,000 80 500 300 100 100 100 100 100 100 100
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5- 2-Ethylidene-1,5- Alfentanyl Fenfluramine Norfentanyl Fenfluramine Norfentanyl JWH-018 5-Pentanoic acid JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-018 5-Pentanoic acid JWH-018 5-Pen	diphenylpyrroi -dimethyl- diphenylpyrroi Fent 600,000 50,000 20 Fent 300,000 25,000 10 Synthetic 300 500 Synthetic 300 300 2500 300 200 10 200	3,3-diphenylpyrrolidine (EDDF) 3,3-diphenylpyrrolidine (EDDF) 3,3-diphenylpyrrolidine (EDDF) idine (EDDP) anyl (FYL20) Buspirone Fentanyl Sufentanyl Sufentanyl Sufentanyl Sufentanyl Marijuana (K2-50) JWH-073 4-butanoic acid JWH-073 4-butanoic acid	300 2100) 100 100 100 50,000 50 25,000 50 500 300 10 2000 2,000 1,000
2-Ethylidene-1,5-dimethyl-3,3- 2-Ethylidene-1,5- 2-Ethylidene-1,5-dimethyl-3,3- Alfentanyl Fenfluramine Norfentanyl Alfentanyl Alfentanyl MH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-018 5-Pentanoic acid JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-03 4-Hydroxypentyl JWH-03 4-Hydroxypentyl JWH-073 4-Hydroxypentyl	diphenylpyrro -dimethyl- diphenylpyrro Fent 600,000 50,000 20 Fent 300,000 25,000 10 Synthetic 50 400 500 Synthetic 30 300 mono-acet 10 200 2,000	3,3-diphenylpyrrolidine (EDDF) 3,3-diphenylpyrrolidine (EDDF) 3,3-diphenylpyrrolidine (EDDF) idine (EDDP) anyl (FYL20) Buspirone Fentanyl Sufentanyl Sufentanyl Marijuana (K2-50) JWH-073 4-butanoic acid JWH-073 4-butanoic acid JWH-075	300 2100) 100 15,000 100 50,000 50 25,000 50 50 50 50 50 50 50 50 50 50 50 50 50 22,000

Morphine 3-β-D-glucuronide	30	Thebaine	200
(±) 3, 4-M	ethylenedi	oxyamphetamine (MDA 5	00)
(±) 3,4-Methylenedioxy	500	Methoxyphenamine	5,000
amphetamine	500	D-Amphetamine	2,000
D,L-Amphetamine sulfate	400	Phentermine	2,000
L-Amphetamine	30,000	Maprotiline	100,000
E	thyl- β-D-G	lucuronide(ETG500)	
Ethyl- β -D-Glucuronide	500	Propyl β-D-glucuronide	50,000
Morphine 3β-glucuronide	100,000	Morphine 6 ^β -glucuronide	100,000
Glucuronic Acid	100,000	Ethanol	>100,000
Methanol	>100,000		
Et	hyl- β-D-Gl	ucuronide(ETG1,000)	
Ethyl- β -D-Glucuronide	1,000	Propyl β-D-glucuronide	100,000
Morphine 3β-glucuronide	>100,000	Morphine 6β-glucuronide	>100,000
Glucuronic Acid	>100,000	Ethanol	>100,000
Methanol	>100.000		

Effect of Urinary Specific Gravity Fifteen (15) urine samples of normal, high, and low specific gravity ranges (1.005-1.045) were spiked with drugs at 50% below and 50% above cut-off levels respectively. The Multi-Drug Rapid Test Cup was tested in duplicate using fifteen drug-free urine and spiked urine samples. The results demonstrate that varying ranges of urinary specific gravity do not affect the test results. Effect of Urinary pH

The pH of an aliquoted negative urine pool was adjusted to a pH range of 5 to 9 in 1 pH unit increments and spiked with drugs at 50% below and 50% above cut-off levels. The spiked, pH-adjusted urine was tested with the Multi-Drug Rapid Test Cup. The results demonstrate that varying ranges of pH do not interfere with the performance of the test.

Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-free urine or drug positive urine containing, Amphetamine, Barbiturates, Benzodiazepines, Buprenorphine, Cocaine, Marijuana, Methadone, Methamphetamine, Methylenedioxymethamphetamine, Morphine, Tramadol ,Ketamine ,Phencyclidine, Propoxyphene or Tricyclic Antidepressants, Oxycodone, Cotinine, EDDP, Fentanyl, Synthetic Marijuana, 6-mono-aceto-morphine, 3, 4-Methylenedioxyamphetamine and Ethyl-6-D-Glucuronide. The following compounds show no cross-reactivity when tested with the Multi-Drug Rapid Test Cup at a concentration of 100 µg/mL.

Non Cross-Reacting Compounds

	NULL CLOSS-LEaC	ang compounds	
Acetophenetidin	Cortisone	Zomepirac	d-Pseudoephedrine
N-Acetylprocainamid	Creatinine	Ketoprofen	Quinidine
Acetylsalicylic acid	Deoxycorticosterone	Labetalol	Quinine
Aminopyrine	Dextromethorphan	Loperamide	Salicylic acid
Amoxicillin	Diclofenac	Meprobamate	Serotonin
Ampicillin	Diflunisal	Methoxyphenamine	Sulfamethazine
I-Ascorbic acid	Digoxin	Methylphenidate	Sulindac
Apomorphine	Diphenhydramine	Nalidixic acid	Tetracycline
Aspartame	Ethyl-p-aminobenzoa	Naproxen	Tetrahydrocortisone,
Atropine	β-Estradiol	Niacinamide	3-acetate
Benzilic acid	Estrone-3-sulfate	Nifedipine	Tetrahydrocortisone
Benzoic acid	Erythromycin	Norethindrone	Tetrahydrozoline
Bilirubin	Fenoprofen	Noscapine	Thiamine
d,I-Brompheniramine	Furosemide	d,I-Octopamine	Thioridazine
Caffeine	Gentisic acid	Oxalic acid	d,I-Tyrosine
Cannabidiol	Hemoglobin	Oxolinic acid	Tolbutamide
Chloral hydrate	Hydralazine	Oxymetazoline	Triamterene
Chloramphenicol	Hydrochlorothiazide	Papaverine	Trifluoperazine
Chlorothiazide	Hydrocortisone	Penicillin-G	Trimethoprim
d,I-Chlorpheniramine	o-Hydroxyhippuric	Perphenazine	d,I-Tryptophan
Chlorpromazine	3-Hydroxytyramine	Phenelzine	Uric acid
Cholesterol	d,I-Isoproterenol	Prednisone	Verapamil
Clonidine	Isoxsuprine	d,I-Propanolol	
_	_		

[BIBLIOGRAPHY]

- Hawks RL, CN Chiang. Urine Testing for Drugs of Abuse. National Institute 1. for Drug Abuse (NIDA), Research Monograph 73, 1986.
- Tietz NW. Textbook of Clinical Chemistry. W.B. Saunders Company. 2. 1986; 1735.
- 3. Stewart DJ, Inaba T, Lucassen M, Kalow W. Clin. Pharmacol. Ther. April 1979; 25 ed: 464, 264-8.
- Ambre J. J. Anal. Toxicol.1985; 9:241. 4.
- Winger, Gail, A Handbook of Drug and Alcohol Abuse, Third Edition, Oxford 5. Press, 1992, page 146.
- Robert DeCresce. Drug Testing in the workplace, 1989 page 114. 6.
- Glass, IB. The International Handbook of Addiction Behavior. Routledge Publishing, New York, NY. 1991; 216 7.

- B. Cody, J.T., "Specimen Adulteration in drug urinalysis. Forensic Sci. 8. Rev., 1990, 2:63.
- C. Tsai, S.C. et.al., J. Anal. Toxicol. 1998; 22 (6): 474 9
- 10. Baselt RC. <u>Disposition of Toxic Drugs and Chemicals in Man</u>. 6th Ed. Biomedical Publ., Foster City, CA 2002.
- 11. Hardman JG, Limbird LE. Goodman and Gilman's: The Pharmacological Basis for Therapeutics. 10th Edition. McGraw Hill Medical Publishing, 2001; 208-209.

145031000 Number: Effective date: 2014-12-10